WO2007018248A1 - ピリドン化合物 - Google Patents
ピリドン化合物 Download PDFInfo
- Publication number
- WO2007018248A1 WO2007018248A1 PCT/JP2006/315775 JP2006315775W WO2007018248A1 WO 2007018248 A1 WO2007018248 A1 WO 2007018248A1 JP 2006315775 W JP2006315775 W JP 2006315775W WO 2007018248 A1 WO2007018248 A1 WO 2007018248A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- pyridine
- compound
- ethyl
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Definitions
- the present invention relates to a novel pyridone compound.
- This compound acts as a melanin-aggregating hormone receptor antagonist, and as a preventive, treatment or therapeutic agent for various cardiovascular diseases, nervous system diseases, metabolic diseases, reproductive system diseases, respiratory diseases, gastrointestinal diseases, etc. Useful.
- MCH Melanin-Concentrating Home Lemon
- MCH-containing neuron cell bodies are localized in the lateral hypothalamic area and inaccurate zone, but their nerve fibers project to a very wide area in the brain [Th J ournalof Comparative Neurology, Vol. 319, 21 8 (1992)], MCH is thought to be responsible for various central functions in the body.
- the lateral hypothalamic area has long been known as a feeding center, and in recent years there has been a wealth of molecular and pharmacological knowledge that suggests its involvement in the control of MHC energy homeostasis. . That is, MCH precursor mRNA expression is increased in the brains of ob / ob mice, dbZdb mice, Ay / a mice, Zuckerfatty rats, and fasted mice, which are genetic obesity model animals.
- mice lacking the MCH precursor gene showed lower food intake and increased oxygen consumption per body weight compared to wild-type mice, and low body weight due to decreased body fat was observed [ Nature, Vol. 396, 670 (1 998)].
- transgenic mice that overexpress MCH precursors exhibit obesity and insulin resistance with overeating [The J ournal of C 1 inica 1 I nvestigation, Vo l.
- MCH is an important factor in obesity formation, and it is suggested that metabolic disorders with obesity as a risk factor are involved in respiratory diseases.
- MCH is known to cause anxiety, acupuncture, memory, learning, diuresis, sodium excretion, roxytocin secretion, and reproductive / sexual function [P eptides, Vo 1, 7 1 71 (1 996); P eptides, Vo l. 18, 1095 (1997); P eptides, Vo l. 15, 757 (1 994); J ournalof Neuroendocrinology, Vo l. 8, 57 (1996); See Critical Re views in Neurology, Vol. 8, 221 (1 994)
- MCH induces various pharmacological actions through MCH receptors mainly present in the central nervous system.
- MCH-1R or SLC-1R or SLC-1 type 1 receptors
- MCH-2R or SLT type 2 receptors
- MCH receptors [Na ture , Vo l. 400, 26 1 (1999); Na ture, Vo l. 400, 265 (1999); B ioch emical and B iop hysical Re search Com uni ations, Vo l. 26 1, 622 (1999) Na ture Cell B iology, Vo l. 1, 267 (1 999); FEB SL etters, Vo l.
- MCH-1R the pharmacological action observed in rodents is mainly induced through MCH-1R [see Genomics, VoI, 79, 785 (2002)]. It is known that MCH-1R gene-deficient mice do not undergo overeating or obesity even when administered live with MCH, and that energy metabolism control by MCH is triggered through MCH-1R. Yes. Furthermore, MCH-1 R deficiency is known to increase mouse activity [Proceedingsofthe National 1. Ac ad emy of Sciencesofthe Un ited Statesof Am erica, Vol. 99, 3240 (2002 ))], And its involvement in central diseases with behavioral abnormalities such as attention deficit / hyperactivity disorder, schizophrenia depression, etc. is strongly suggested [Molecular Medicine To day, Vol. , 43 (2000); see T rendsin N euroscience, Vol, 24, 527 (2001)].
- MCH The function of MCH is expressed by binding of MCH to the MCH receptor. Therefore, inhibition of MCH receptor binding can block the expression of MCH action. Therefore, substances that antagonize receptor binding of MCH are various diseases involving MCH, such as obesity, diabetes, abnormal hormone secretion, hyperlipidemia, gout, fatty liver, etc .; Angina pectoris, acute ⁇ congestive heart failure, myocardial infarction, atherosclerosis, hypertension, kidney disease, electrolyte disorders, etc .; eg, bulimia, affective disorder, depression, anxiety, hemorrhoids, delirium, dementia Central and peripheral nervous system diseases such as schizophrenia, attention deficit / hyperactivity disorder, memory disorder, sleep disorder, cognitive disorder, movement disorder, sensory abnormality, olfactory disorder, morphine tolerance, narcotic dependence, alcoholism For example, fertility diseases such as infertility, premature birth, sexual dysfunction, etc. Others are expected to be useful as preventive, treatment or therapeutic agents for gastrointestinal diseases, respiratory diseases
- Examples of compounds having an MCH receptor antagonistic action include, for example, International Publication WOO 1.Z 21 577, W0hi 1/82925, WO02 / 06245, W02 / 02 744, etc. Although various compounds are disclosed, none of them has a pyridone ring.
- Patent Document 1 discloses a pyridone derivative having antihyperglycemic activity.
- the _Y — Y 2 _Y 3 — moiety in the formula of the present invention is a single bond, and the L and ⁇ 2 moieties are also single bonds.
- ⁇ 2 , ⁇ 3 , ⁇ L and ⁇ 2 do not all become single bonds at the same time, and are different from Patent Document 1.
- the literature does not describe MCH receptor antagonism.
- Patent Document 2 discloses a pyridone derivative having 38-kinase kinase activity.
- methylene is disclosed as one W- moiety in the formula of the present invention.
- the linker is different in that the main chain has 2 or more atoms.
- the literature does not describe MC ⁇ receptor antagonism.
- Patent Literature 1 International Publication WOO 2 ⁇ 81454 Pamphlet
- Patent Document 2 International Publication WO 03 68230 Pamphlet
- the present inventors have conducted extensive studies on compounds having MCH receptor antagonism. As a result, an aromatic 6-membered ring is bonded to the N atom of the pyridone ring via a linker having 2 or more main chain atoms, and a specific amino group is attached to the para-position of the aromatic 6-membered ring via a linker.
- the present pyridone compound has an MCH receptor antagonistic action, and is found to be effective for the prevention and treatment of various diseases related to the MCH receptor, thereby completing the present invention. .
- 1 ⁇ and 1 2 are the same or different and each represents a hydrogen atom, an optionally substituted lower alkyl group or an optionally substituted lower alkyl group, and And R 2 together with the nitrogen atom to which they are bonded, optionally having a 4- to 1-membered, bridged, non-bridged or spirocyclic aliphatic nitrogen-containing heterocycle. May be formed,
- 1 and 2 represent methine optionally substituted with a substituent selected from the group consisting of group ⁇ , methine or nitrogen atom substituted with Ar—Y 2 —Y 3 —,
- 3 and 4 are the same or different and each represents an optionally substituted methine or nitrogen atom
- x 5 , x 6 , x 7 and x 8 are the same or different and optionally have a substituent.
- Y 2 represents a single bond, an optionally substituted lower alkylene group, an optionally substituted lower alkenylene group or an optionally substituted lower cycloalkylene group,
- Upsilon 3 represents a single bond, one o-, - NR-, One S-, one SO- or single S_ ⁇ 2 -;
- R represents a hydrogen atom or an optionally substituted lower alkyl group
- W represents one (O) — (CH 2 ) n ⁇ ( ⁇ ) m 2 —, and one (CH 2) n— in W may optionally have a substituent,
- M 2 is the same or different and represents 0 or 1
- n represents an integer of 1 to 4 and satisfies S rr ⁇ + ms + n ⁇ , where m 2 and n are m Never be 1 at the same time,
- L represents a single bond or an optionally substituted methylene group, and L is optionally substituted with an adjacent nitrogen atom together with Z 2 and May form an aliphatic nitrogen-containing heterocyclic ring, which represents a single bond, 10- or an optionally substituted C 4 alkylene group,
- Z 2 represents a single bond or an optionally substituted alkylene group
- Ar is an optionally substituted aromatic carbocyclic group, optionally having a substituent, aromatic heterocyclic group or optionally having a substituent. Which represents a good aliphatic carbocyclic group], or a pharmaceutically acceptable salt thereof.
- the present invention provides:
- Melayun-concentrating hormone receptor antagonist comprising the compound according to (1) or a pharmaceutically acceptable salt thereof as an active ingredient
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound according to (1) or a pharmaceutically acceptable salt thereof,
- Metabolic diseases represented by liver, hepatitis and cirrhosis; angina pectoris, acute congestive heart failure, myocardial infarction, annular arteriosclerosis, hypertension, kidney disease and electrolyte abnormalities; bulimia , Affective disorder, depression, anxiety, hemorrhoids, delirium, dementia, schizophrenia, attention deficit / hyperactivity disorder, memory disorder, sleep disorder, cognitive disorder, movement disorder, abnormal sensation, olfactory disorder, morphine tolerance, narcotic Central and peripheral nervous system diseases represented by addiction and alcoholism; reproductive system diseases represented by infertility, preterm birth and sexual dysfunction; gastrointestinal diseases; respiratory diseases; prevention of cancer or skin pigmentation; Treatment or therapeutic agent, To provide.
- the term “lower” means that the group or compound to which this word is attached has 6 or less carbon atoms, preferably 4 or less.
- the “lower alkyl group” includes a straight-chain or branched alkyl group having 1 to 6 carbon atoms, specifically, for example, a methyl group, an ethyl group, n— Propyl group, .Isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert_butyl group, n-pentyl group, isopentyl group, neopentyl group, tert-amyl group, .1-methylbutyl group, 2- Methylbutyl group, 1,2-dimethylpropyl group, 1-ethylpropyl group, n-hexyl group, isohexyl group, 1-methylpentyl group, 2-methylpentyl group, 3-methylpentyl group, 1, 1 Dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group, 1-1-ethylbutyl
- the “lower cycloalkyl group” includes a cycloalkyl ′ group having 3 to 6 carbon atoms, and specific examples include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group.
- the “lower alkylene group” includes a linear alkylene group having 1 to 6 carbon atoms or a branched alkylene group having 3 to 6 carbon atoms. Specifically, for example, a methylene group, an ethylene group, a propylene group, Examples include a butylene group, a pentylene group, and a hexylene group.
- a “lower alkenylene group” has 2 carbon atoms with one carbon-carbon double bond in the chain.
- -6 straight-chain or C3-C6 branched alkylene groups are included, such as vinylene group, 1-propenylene group, 2-propylene group, 1 —Buteneylene group, 2-Butenylene group, 3-Butenylene group, 2-Pentenylene group, 3-Pentenylene group, 4_Pentenylene group, 1_Hexelene group, 2-Hexenylene group , 3-hexenylene group, 4-hexenylene group, 5-hexenylene group and the like.
- the “lower cycloalkylene group” includes a cycloalkylene group having 3 to 6 carbon atoms. Specifically, for example, 1, 1-cyclopropylene group, 1,2-cyclopropylene group, 1, 1 —Cyclobutanylene group, 1,2-cyclobutanylene group, 1,3-Cyclobutanylene group, 1,1-cyclopentylene group, 1,2-cyclohexylene group, 1,3-cyclohexylene group 1, 4-cyclohexylene group and the like. ..
- substituent in the “methine optionally having a substituent” include a substituent selected from the group consisting of groups.
- Optionally substituted lower alkyl group “optionally substituted lower cycloalkyl group”, “optionally substituted lower alkylene group” , “Alkylene optionally having substituent (s)”, “lower alkenylene group optionally having substituent (s)” and “methylene optionally having substituent (s)”
- substituent include a substituent selected from the group consisting of group / 3, and the group such as the lower alkyl group may be substituted with one or more of these substituents. Monkey.
- a fluorine atom Good lower alkyloxy group, lower alkyloxy lower alkyl group, lower alkyloxycarbonyl group, lower alkyloxycarbonylamino group, lower alkyloxycarbonylamino (lower alkyl) amino group, lower alkylcarbonyl group, lower alkyl Carbonyloxy group, lower alkylcarbonylamino group, lower alkylcarbonyl (low Secondary alkyl) Amino group, Forced rubermoyl group, Mono lower alkyl force ruberamoyl group, Di Lower alkyl force ruberamoyl group, Powered ruvamo
- An “aliphatic nitrogen-containing heterocyclic group” contains at least 1, preferably 1 to 3 nitrogen atoms as part of the ring members and in some cases more 0 to 2 oxygen atoms or 0 to 2 3 to 7-membered monocyclic or 5- to 12-membered polycyclic saturated or partially unsaturated heterocyclic group, which may contain a sulfur atom of Aziridinyl group, azetidinyl group, pyrrolidinyl group, piperidinyl group, homopiperazinyl group, homopiperidinyl group, morpholinyl group, thiomorpholinyl group, octahydrocyclopenta [b] pyrrolyl group, hexydropyrrolidinyl group, octahydrindyl hydridinyl group Group, octahhi, dropirido [2.1-C] oxazyl group, 2,5,6,7-tetrahydrol-5H-pyro-
- aromatic carbocyclic group includes monocyclic or polycyclic aromatic carbocyclic groups having 6 to 14 carbon atoms, preferably 6 to 10 carbon atoms. Examples include a phenyl group, a naphthyl group, a phenanthryl group, and the like.
- the “aromatic heterocyclic group” is a 5- to 6-membered monocycle containing at least one, preferably 1 to 5, heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom force as a part of the ring members.
- an 8- to 14-membered polycyclic heteroaromatic cyclic group specifically, for example, pyridinyl group, pyrimidinyl group, pyridazinyl group, virazyl group, pyrazolyl group, pyrrolyl group, imidazolyl group , Triazolyl group, oxazolyl group, isoxazolyl group, oxadiazolyl group, thiazolyl group, isothiazolyl group, thiadiazolyl group, tetrazolyl group, pyridazinyl group, pyrajuryl group, furyl group, 'Chenyl, indolyl, benzofuranyl, benzocenyl, benzoimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzothiazolyl, indazolyl, pre- Group, quinolyl group, isoquinolyl group, phthal
- “Aliphatic carbocyclic group” includes monocyclic or polycyclic saturated or partially unsaturated carbocyclic groups having 3 to 10 carbon atoms, preferably 3 to 8 carbon atoms. Examples include a cyclopropyl group, a cyclobutenyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclohexyl group, a cyclodecyl group, a bicyclohexyl group, an adamantyl group, and the like. .
- Examples of “4- to 1-membered bridged, non-bridged or spirocyclic aliphatic nitrogen-containing heterocycles” include, for example, 2,5-diazabicyclo [2. 2. 1] peptane as a bridged aliphatic nitrogen-containing heterocycle. 2, 5—Zazabicyclo. [2. 2. 2] Octane ', octahdro pier mouth [3.4 — b] Pyrrole', octahdro pier mouth [3.4-c] pyrrole, 3-azabicyclo [3. 1. 0] hexane, decahydropyro [3.
- azepine, etc., and non-bridged aliphatic nitrogen-containing heterocycles include azetidine ring, pyrrolidine ring, piperidine ring, hexane Examples include methyleneimine ring, heptamethyleneimine ring, morpholine ring, etc.
- Nonane, 3 Oxa 1, 7—Gizaspiro [4.4] Nonane ', 2, 7—Diazaspiro [4. 4] Nonane, 2, 7—Gazaspiro [3.5] Nonane,' 2—Azaspiro [3.3] heptane, 2—Oxa_ 6—Azaspiro [3.3] heptane, 2, 8—Zazaspiro [4.5] Decane.
- the substituent in the “aromatic heterocyclic group optionally having substituent (s)” or the “aromatic carbocyclic group optionally having substituent (s)” is selected from the group consisting of groups.
- the selected substituents are exemplified, and the above cyclic group may be substituted with one or more of these substituents.
- substituents in “aliphatic nitrogen-containing heterocyclic group optionally having substituent (s)” or “aliphatic carbocyclic group optionally having substituent (s)” include group 13 In addition to a substituent selected from the group consisting of: an oxo group, a lower cycloalkyl The above cyclic group can be substituted with one or more of these substituents.
- substituent in the “lower alkyl group optionally having substituent (s)” defined for R for example, a halogen atom, a lower alkyl group, and a lower haloalkoxy group are preferable. is there.
- halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
- the “lower alkyl group optionally substituted with a fluorine atom or a hydroxyl group” includes a lower alkyl group in which part or all of the hydrogen atoms of the lower alkyl group or lower alkyl group are substituted with a fluorine atom or hydroxyl group.
- Examples of the lower alkyl group substituted with a fluorine atom or a hydroxyl group include, for example, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a 2-fluoroethyl group, a 1,2-difluoroethyl group, and a 2-hydroxy group. Examples include droxetyl group and 1,2-dihydroxychetyl group.
- the “lower alkyloxy group optionally substituted with a fluorine atom” includes a group in which a lower alkyl group or a lower alkyl group substituted with a fluorine atom is bonded to an oxygen atom.
- the alkyloxy group include a methoxy group, an ethoxy group, an n-propyloxy group, an isopropyloxy group, an n-butoxy group, an isobutoxy group, a tert-butoxy group, and an n-pentyloxy group, and substituted with a fluorine atom.
- the lower alkyloxy group include a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a 1,2-difluoroethoxy group, and the like.
- “Mono-lower alkylamino group” is a group in which one hydrogen atom of an amino group (one NH 2 ) is substituted with a lower alkyl group. Specifically, for example, a methylamino group, an ethylamino group, n-propylamino group, and the like. Group, isopropylamino group, n-butylamino group, sec-butylamino group, tert-butylamino group and the like.
- the “di-lower alkylamino group” is a group in which two hydrogen atoms of an amino group (one NH 2 ) are substituted with a lower alkyl group.
- a dimethylamino group a dimethylamino group, an ethyl group, and the like.
- examples include a methylamino group, a di (n-propyl) amino group, a methyl (n-propyl) amino group, and a diisopropylamino group.
- the “lower alkyloxy lower alkyl group” is a lower alkyl group substituted with a lower alkyloxy group, and specifically includes, for example, a methoxymethyl group, a methoxymethyl group, an n-propyloxymethyl group, and an isopropyloxymethyl group.
- a “lower alkyloxycarbonyl group” is a group in which a lower alkenyloxy group is bonded to a carbonyl group (one CO—), and includes an alkyloxycarbonyl group having 1 to 6 carbon atoms.
- methoxycarbonyl group, ethoxycarbonyl group, n-propyloxycarbonyl group, isopropyloxycarbonyl group, n_butoxycarbonyl group, isobutoxycarbonyl group, tert-butoxycarbonyl group, n-pentylo Examples include a xylcarbonyl group.
- the “lower alkyloxycarbonylamino group” is a group in which a lower alkyloxycarbonyl group is bonded to an amino group (one NH 2 ) and includes an alkyloxycarbonylamino group having 1 to 6 carbon atoms. Specifically, for example, methoxycarbonylamino group, ethoxycarbonylamino group, n-propyloxycarbonylamino group, isopropyloxycarbonylamino group, n-butoxycarbonylamino group, isobutoxycarbonyl group, And a mino group, a tert-butoxycarbonylamiso group, and an n-pentyloxycarbonylamino group.
- a “lower alkyloxycarbonyl (lower alkyl) amino group” is a group in which a lower alkyloxycarbonyl group is bonded in place of a hydrogen atom on the nitrogen atom of a mono-lower alkylamino group.
- a methoxy carbonyl (methyl) amino group, an ethoxy carbo yl (methyl) amino group, an n-propyloxy carbonyl (methyl) amino group and the like can be mentioned.
- the “lower alkylcarbonyl group” is a group in which a lower alkyl group is bonded to a carbonyl group (—CO—) and includes an alkylcarbonyl group having 1 to 6 carbon atoms. Specifically, for example, a acetyl group And propiool group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, and bivaloyl group.
- the “lower aralkylcarbonyloxy group” is a group in which a lower alkylcarbonyl group is bonded to an oxygen atom. Specifically, for example, an acetoxy group, a propionoxyl group, a valeryloxy group, an isovaleryloxy group And bivalloyloxy group.
- a “lower alkylcarbonylamino group” is a group in which one hydrogen atom of an amino group (one NH 2 ) is substituted with a lower alkylcarbonyl group.
- Examples include a cetoamide group, a propionylamino group, a isobutyrylamino group, a nonrelylamino group, an isovalerylamino group, and a bivalylamino group.
- a “lower alkylcarbonyl (lower alkyl) amino group” is a group in which a hydrogen atom on the nitrogen atom of a mono-lower alkylamino group is substituted with a lower alkylcarbonyl, such as a methylcarbonyl (methyl) amino group, an ethylcarbonyl ( And methyl ') amino group, n-propylcarbonyl'methyl (methyl) amino group and the like.
- “Mono-lower alkyl-powered rubermoyl group” is a group in which one of the hydrogen atoms of the force-based rubermoyl group (one CONH 2 ) is substituted with a lower alkyl group. Specifically, for example, a methylcarbamoyl group, an ethylca-rubamoyl group N-propyl-powered rubermoyl group, isopropyl-powered rubermoyl group, n-butylcarbamoyl group, sec-butylcarbamoyl group, tert-butylcarbamoyl group and the like.
- Di-lower alkyl force Rubamoiru group means a group in which two hydrogen atoms of the force Rubamoiru group (one C_ ⁇ _NH 2) is substituted with a lower alkyl group, specifically, for example, dimethyl Ji carbamoyl group, Jechinore
- rubamoyl group, ethylmethylcarbamoyl group, di (n-propyl) rubamoyl group, methyl (11-propyl) rubamoyl group, disopropyl rubamoyl 'group and the like can be mentioned. '
- the “mono lower alkyl strength ruberamoylamino group” is a group in which one of the hydrogen atoms of the amino group (—NH 2 ) is substituted with a mono lower alkyl strength ruberamoyl group.
- a methylcarbamoylamino group examples thereof include a tilcarbamoylamino group, an 11-propyl rubamoylamino group, an isopropyl rubamoyl'amino group, an n-butyl carbamoylamino group, a sec-butylcarbamoylamino group, and a tert-butyl carbamoylamino group.
- a “di-lower alkyl strength ruberamoylamino group” is a group in which one of the hydrogen atoms of the amino group (—NH 2 ) is substituted with a di-lower alkyl strength ruberamoyl group, specifically, for example, a dimethylcarbamoylamino group.
- Jetylcarbamoylamino group Di (n-propyl) force ruberamoylamino group, Disopropyl force ruberamoyl 'amino group, Di (n-butyl) force ruberamoylamino group, Di (sec-butyl) force ruberamoylamino group, Di (tert- (Ptyl) Forced ruberamolymif group and the like.
- “Mono-lower alkyl strength ruberamoyl (lower alkyl ') amino group” is a group in which the hydrogen atom on the nitrogen atom of mono-lower alkylamino group is replaced with mono-lower alkyl strength ruberamoyl group. Monomethylcarbamoyl (methyl) amino group, monoethylcarbamoyl (methyl) amino group, [mono (n-propyl ') force Rubamoyl '] (methyl) amino group and the like.
- the “di-lower alkyl strength ruberamoyl (lower alkyl) amino group” is a group in which the hydrogen atom on the nitrogen atom of the “mono lower alkyl alkyl group” is substituted with the di-lower alkyl strength ruberamoyl group. Examples thereof include dimethylcarbamoyl (methyl) amino group, jetylcal'bamoyl (methyl) amino group, and [di (11-propyl rubamoyl)] (methyl) amino group.
- “Mono-lower alkyl group rubamoyloxy group” is a group in which a mono-lower alkyl group rubamoyl group is bonded to an oxygen atom. Specifically, for example, a methylcarbamoyloxy group, an ethylcarbamoyloxy group, an n-propyl group rubamoyloxy group. Group, isopropyl force ruberamoyloxy group, n-butylcarbamoyloxy group, sec-butylcarbamoyloxy group, tert-butylcarbamoyloxy group and the like.
- a “di-lower alkyl strength ruberamoyloxy group” is a group in which a di-lower alkylcarbamoyl group is bonded to an oxygen atom, specifically, for example, dimethylcarbamoyloxy group, jetylcarbamoyloxy group, ethylmethyl Examples thereof include a carbamoyloxy group, a di (n-propyl) -powered ruberamoyloxy group, a methyl (n-propyl) -powered rubermolyoxy group, and a disopropyl-powered ruberamoyloxy group.
- the “lower alkylsulfonyl group” is a group in which a lower alkyl group is bonded to a sulfonyl group (—so 2 ).
- examples thereof include a sulfol group, n-butyl sulphonyl group, sec-butinolesnolephonyl group, tert-butinolesnolephonyl group and the like.
- a “lower alkylsulfo-lumino group” is a group in which one hydrogen atom of an amino group (one NH 2 ) is substituted with a lower alkylsulfonyl group, and specifically includes, for example, a methylolsulfonylamino group, an ethylsulfo group, and the like.
- lower alkylsulfonyl (lower alkyl) amino group is a group in which a hydrogen atom on a nitrogen atom of a mono-lower alkylamino group is substituted with a lower alkylsulfonyl group, specifically, for example, a methanesulfonyl group, ethane Examples include a sulfonyl group, n-propansulfonyl group, and isopropanesulfonyl group.
- a “mono-lower alkyl sulfamoyl group” is a group in which one of the hydrogen atoms of a sulfamoyl group (_S 0 2 NH 2 ) is substituted with a lower alkyl group.
- monomethyl sulfamoyl group Group monoethyl sulfamoyl group, mono (n-propyl) sulfamoyl group, monoisopropinolesnorefamoyl group, mono (n-butyl) sulfamoyl group, mono (sec-ptyl) sulfamoyl group, mono ( tert monobutyl) sulfamoyl group and the like.
- the “di-lower alkylsulfamoyl group” is a group in which two hydrogen atoms of a sulfamoyl group (one S 0 2 NH 2 ) are each substituted with a lower alkyl group, specifically, pill ′) sulfamoyl group, Examples thereof include a diisopropylsulfamoyl group, a di (n-butyl) sulfyl group, a di (sec-butyl ′) sulfamoyl group, and a di (tert-butyl) sulfamoyl group.
- the “mono-lower alkylsulfamoylamino group” is a group in which one hydrogen atom of an amino group (one NH 2 ) is substituted with a mono-lower alkylsulfamoyl group.
- (monomethylsulfamoyl group) (Famoyl) amino group, (monoethylsulfamoyl) amino group, [mono (n-propyl) sulfamoyl] amino group, (monoisopropylsulfamoyl) amino group, [mono (n-butyl) sulfamoyl] amino group
- Examples include [(mono sec-butyl) sulfamoyl] amino group, [mono (tert-butyl) sulfamoyl] amino group, and the like.
- “(Di-lower alkylsulfamoyl) amino group” is a group in which one of the hydrogen atoms of the amino group (—NH 2 ) is substituted with a di-lower alkylsulfamoyl group.
- “Mono-lower alkylsulfamoyl (lower alkyl) amino group” is a group in which a hydrogen atom on the nitrogen atom of a mono-lower alkylamino group is substituted with a mono-lower alkylsulfamoyl group.
- monomethyl examples include sulfamoyl (methinole) amino group, monoethyl sulfamoyl (methyl;) amino group, [mono (n-propyl) sulfamoyl] (methyl ') amino group, and the like.
- “Di-lower alkylsulfamoyl (lower alkyl) amino group” means that the hydrogen atom on the nitrogen atom of the mono-lower alkylamino group is replaced with the di-lower alkylsulfamoyl group. More specifically, for example, dimethylsulfamoyl (methyl) amino group, jetylsulfamoyl (methyl) amino group, [di (n-propyl) snolefamoyl] (methyl) amino group, etc. Is mentioned.
- the “pharmaceutically acceptable salt” of the pyridone compound represented by the formula [I] includes a pharmaceutically acceptable ordinary salt, and an acid addition salt at the amino group of the compound of the formula [I] Or, an acid addition salt in a nitrogen-containing heterocyclic ring, or a base addition salt in the force ruboxyl group when the compound of the formula [I] has a carboxyl group is exemplified.
- Examples of the acid addition salts include hydrochlorides, sulfates, nitrates, phosphates, perchlorates, and other inorganic acid salts, maleates, fumarate, tartrate, citrate, ascorbate, trifluoro Organic acid salts such as acetates; sulfonates such as methane sulfonates, isethionates, benzene sulfonates, and p-toluene sulfonates.
- the base addition salt examples include alkali metal salts such as sodium salt and strong salt; alkaline earth metal salts such as calcium salt and magnesium salt; ammonium salt, trimethylamine salt, triethylamine salt, dicyclohexylamine salt And ethanolamine salts such as ethanolamine salt, diethanolamine salt, triethanolamine salt, pro-electron salt, and N, N'-dibenzylethylenediamine salt.
- alkali metal salts such as sodium salt and strong salt
- alkaline earth metal salts such as calcium salt and magnesium salt
- ammonium salt trimethylamine salt, triethylamine salt, dicyclohexylamine salt
- ethanolamine salts such as ethanolamine salt, diethanolamine salt, triethanolamine salt, pro-electron salt, and N, N'-dibenzylethylenediamine salt.
- X and x 2 are methine optionally having a substituent selected from the group consisting of group hi, methine substituted with Ar 1 Y 2 — Y 3 — or Represents a nitrogen atom, and one of and 2 is methine substituted with A r——Y 2 —Y 3 —, and the other is optionally substituted with a substituent selected from the group consisting of a group of groups. It is a methine or nitrogen atom that may be present.
- substituent selected from the group opportunistic group consisting in chi 2 is a fluorine atom, a chlorine atom, a methyl group, main butoxy group and the like.
- Xi is a methine optionally having a substituent selected from the group consisting of a group of methine
- X 2 is a methine substituted with Ar — — Y 2 — Y 3 ,
- X is a nitrogen atom
- X 2 is A r- Y - Y 2 - methine substituted by Y 3, and the like, preferably, have a substituent X, but is selected from the group opportunistic group consisting optionally A methine in which ⁇ 2 is replaced by A r— — ⁇ 2 — ⁇ 3 ,
- Upsilon 1 is a single bond, One 0_, - NR-, One S-, one SO- or single S_ ⁇ 2 - was table,
- Y 2 is a single bond, an optionally substituted lower alkylene ′, an optionally substituted group, a lower alkylene or an optionally substituted group. Represents a good lower cycloalkylene group,
- Upsilon 3 represents a single bond, One ⁇ _, - NR-, One S-, one SO- or - S_ ⁇ 2 - was table,
- R represents a hydrogen atom or a lower alkyl group optionally having a substituent.
- Y 2 is preferably a single bond, an optionally substituted methylene group, an optionally substituted vinylene group or an optionally substituted ethylene. Examples are groups.
- Upsilon 3 represents a single bond or one ⁇ - is exemplified.
- Ar may optionally have an aromatic carbocyclic group which may have a substituent, may optionally have an aromatic heterocyclic group which may have a substituent, or may optionally have a substituent. Represents an aliphatic carbocyclic group.
- substituents in “substituent optionally having a substituent” in Ar include a substituent selected from the group consisting of Group 5, a phenol group, a phenoxy group, and the like. Among them, those selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group, a methoxy group, a trifluoromethyl group, a difluoromethoxy group, and a trifluoromethoxy group are recommended.
- a phenyl group optionally having a substituent or a pyridinyl group optionally having a substituent is preferable, more preferably a phenyl group, a 4-chlorophenyl group, 4- Preference is given to the groups such as funoleoropheninole group, 4-trifluoromethyloxyphenole group, 2_pyridinyl group, 5-funoleothiol 2-pyridinyl group, 5-chlorodioctyl 2-pyridinyl group and the like.
- X 3 and X 4 are the same or different and each represents an optionally substituted methine or nitrogen atom.
- the combination of X 3 and X 4 is preferably
- X 3 and X 4 may optionally have a substituent, or
- One of X 3 and X 4 is a nitrogen atom, and the other is optionally a methine optionally having a substituent, and in particular, both are unsubstituted methine, Or one of X 3 and X 4 is a nitrogen atom and the other is unsubstituted methine.
- X 5 , X 6 , X 7 and X 8 are the same or different and each represents an optionally substituted methine or nitrogen atom, provided that X 5 , X 6 , X 7 and X 8 Of these, more than 3 atoms cannot become nitrogen atoms at the same time.
- x 5 , x 6 , x 7 and x 8 are all preferably methine optionally having a substituent, and in particular, optionally halogen or lower alcohol. Methine substituted with a xy group or unsubstituted methine is recommended.
- W represents one (O) — (CH 2 ) n- (O) m 2 —, and one (CH 2 ) n— in W may optionally have a substituent.
- n represents an integer of 1 to 4, and 2 ⁇ m 1 + m 2 + n ⁇ 4, where mi , m 2 and n cannot be 1 at the same time.
- L represents a single bond or an optionally substituted methylene, and L represents Z 2 and 1 i together, and R 1 together with the adjacent nitrogen atom optionally represents a substituent. May form an aliphatic nitrogen-containing heterocycle that may have,
- Z 1 represents a single bond, -O1 or an alkylene group which may optionally have a substituent
- Z 2 represents a single bond or a Ci-4 alkylene group optionally having a substituent.
- Y have Y 2, Y 3, L, and all Z 2 do not become single bond simultaneously.
- L is preferably a single bond or a methylene optionally having a substituent.
- (1) is preferably a single bond, optionally substituted methylene or 1o-.
- z 2 is preferably a single bond or optionally methylene or an optionally substituted substituent.
- alkylene parts may optionally have a substituent, more preferably,
- alkylene moieties may optionally have a substituent, and the optional substituent is preferably selected from the group consisting of group ⁇ Substituents are recommended.
- R 2 are the same or different and represent a hydrogen atom, an optionally substituted lower alkyl group or an optionally substituted lower cycloalkyl group, and 1 ⁇ And R 2 together with the nitrogen atom to which they are attached, optionally with a substituent 3 to 1 1-membered, bridged, unbridged or spirocyclic aliphatic nitrogen-containing heterocycle A ring may be formed.
- Ci_ which may have a location substituent by 4 alkyl group or an optionally may have a substituent C 3 _ 6 cycloalkyl group Is mentioned.
- Z 2 , L and R are formed by joining together adjacent nitrogen atoms, and may optionally have a substituent, preferably as an aliphatic nitrogen-containing heterocycle, A pyrrolidine ring which may have a hydrogen atom is recommended, and as the optional substituent, a substituent selected from the group consisting of group a is recommended.
- 1 1 and 1 2 are formed together with the nitrogen atom to which they are attached, “optionally substituted 3 to 1 1 membered, cross-linked, non-cross-linked or Pyrocyclic aliphatic nitrogen-containing heterocyclic ring is preferably an azetidine ring optionally having a substituent, a pyrrolidine ring optionally having a substituent, and optionally having a substituent.
- an azetidinyl group which may optionally have a substituent, and a pyrrolidinyl group which may optionally have a substituent are recommended.
- a substituent selected from the group consisting of a group and the like is recommended.
- the compound of the present invention is preferably
- the compound represented by the formula [I] can be produced, for example, by the following method. However, the production method of the compound of the present invention is not limited to these reaction examples. Manufacturing method 1
- Production method 1 is a method of condensing a compound represented by the formula [II a] and a compound represented by the formula [I lia] by Mitsunobu reaction to obtain a compound represented by the formula [I ⁇ _a]. is there.
- X p and X 2 p each represents a methine, Dp or nitrogen atom which may optionally have a substituent selected from the group consisting of groups]
- Dp is a methine or nitrogen atom optionally having a substituent selected from the group consisting of a group of groups, Dp is the following formula (a) or formula (b)
- Ar p is an optionally substituted aromatic carbocyclic group, optionally having a substituent, aromatic heterocyclic group or optionally having a substituent. Represents an optionally substituted aliphatic carbocyclic group,
- y l P represents a single bond, —0—, —NR—, —S—, —SO— or one SO 2 —
- y 2 p represents a single bond, an optionally substituted lower alkylene group, an optionally lower alkenylene group or an optionally substituted lower cycloalkylene group,
- y 3 p represents a single bond, 101, -NR-, 1 S-, 1 SO- or 1 S0 2- , and R may be a hydrogen atom or optionally have a substituent. Represents a lower alkyl group,
- Rb is the following formula (A) or formula (B)
- L p represents a single bond or optionally a methylene group optionally having a substituent
- Z 2 p represents a single bond or an optionally substituted C ⁇ 4 alkylene group
- 1 1 and 1 2 may be the same or different and each may have a hydrogen atom or, optionally, a substituent! /, Represents a lower alkyl group or an optionally substituted lower cycloalkyl group, and optionally has a substituent together with the nitrogen atom to which p and R 2 p are bonded together.
- You may have 4 to 1 members, It may form a bridged, non-bridged or spiky ring aliphatic nitrogen-containing heterocycle,
- Z 3 p represents a single bond or an optionally substituted Ci 4 alkylene group
- P 2 represents a protecting group
- the compound represented by the formula [IV-a] is obtained by condensing the compound represented by the formula:
- azodicarbonyl compounds include dimethyl azodicarboxylate, jet lyazodicarboxylate, disopropyl azodicarboxylate, di-tert-butyl tyrazodicarboxylate, 1, 1 '. ) Dipiperidide and the like, and examples of the triarylphosphine include triphenylphosphine and tritolyl'phosphine, and examples of the trialkylphosphine include triethylphosphine, tributylphosphine, and trioctylphosphine.
- the use amount of the compound represented by the formula [III a] is, for example, 1 mol to 3 mol, preferably 1 mol to 1.5 mol, relative to 1 mol of the compound represented by the formula [I la]. Is recommended.
- the amount of the azodicarbonyl compound and the organophosphorus compound used is 1 to 5 moles, preferably 1 to 3 moles per mole of the compound represented by the formula [II a].
- 1 mol to 5 mol of an organic phosphorus compound is exemplified with respect to 1 mol of the compound represented by the formula [II a], and preferably 1 mol to 3 mol is recommended.
- Reaction solvents include: halogenated carbons such as methylene chloride, chloroform, dichloroethane, and carbon tetrachloride; aliphatic hydrocarbons such as n-heptane and n-hexane; aromatics such as benzene, toluene, and xylene Hydrocarbons: Jetyl ether, Tetrahydrofurofuran (hereinafter referred to as “THF”), Dioxane, Ethylene glycol Ethers such as dimethyl ether; Esters such as methyl acetate and ethyl acetate; Acetonitrile, N-methylolpyrrolidone (hereinafter referred to as “NMP”), N, N, 1 dimethylformamide (hereinafter referred to as “DMF”) ), Dimethyl sulfoxide (hereinafter referred to as “DMSO”), or a mixed solvent thereof.
- halogenated carbons such as methylene chloride, chlor
- the reaction temperature is, for example, 0 ° C to 100 ° C, preferably 0 ° C to 50 ° C is recommended, and the reaction is usually completed in 2 hours to 24 hours.
- Production method 2 condenses a compound represented by the formula [I I a] and a compound represented by the formula [I I I b] to obtain a compound represented by the formula [I V—a].
- halogen such as chlorine and bromine
- a leaving group such as a benzenesulfonyloxy group, a ⁇ -toluenesulfonyloxy group, a methanesulfonyloxy group
- W Rb, Xj p, X 2 p , X 3 , X 4 , X 5 , X 6 , 7 and 8 are the same as described above.
- a compound represented by the formula [IV-a] is obtained by condensing a compound represented by the formula [II a] and a compound represented by the formula [II lb] in a reaction solvent in the presence of a base. Can be obtained.
- Bases include inorganic bases such as cesium carbonate, sodium carbonate, carbonated lithium, sodium hydride, hydrogen hydride, cesium fluoride, sodium hydroxide, and potassium hydroxide; sodium tert-butoxide, potassium tert-butoxide An organic base such as
- the amount of the compound represented by the formula [II a] is exemplified by 1 to 5 mol, preferably 1 to 3 mol based on 1 mol of the compound represented by the formula [III b]. .
- the base it can be 1 to 3 mol, preferably 1 to 2 mol, per 1 mol of the compound represented by the formula [I I a]. .
- reaction solvent examples include halogenated carbons such as methylene chloride, black mouth form, dichloroethane, and carbon tetrachloride; n aliphatic hydrocarbons such as n- heptane and n- hexane; Examples include aromatic hydrocarbons such as benzene, toluene, xylene; ethers such as jetyl ether, THF, dioxane, ethylene glycol dimethyl ether; solvents such as acetonitrile, NMP, DMF, DMSO, and mixed solvents thereof It is done.
- halogenated carbons such as methylene chloride, black mouth form, dichloroethane, and carbon tetrachloride
- n aliphatic hydrocarbons such as n- heptane and n- hexane
- aromatic hydrocarbons such as benzene, toluene, xylene
- ethers such as jetyl ether, T
- reaction temperature examples include 0 X:. To 300 ° C, preferably 20 ° C to 150 ° C is recommended, and the reaction is usually completed in 30 minutes to 24 hours.
- the protecting group for the amino group and imino group is not particularly limited as long as it has the function.
- benzyl group, ⁇ -methoxybenzyl group, 3,4-dimethoxybenzinore group, ⁇ —Aralkyl groups such as nitrobenzyl group, ⁇ -nitrobenzyl group, benzhydryl group, trityl group; lower alkyl group such as formyl group, acetyl group, propionyl group, ptylyl group, bivayl group, etc.
- a benzoyl group an arylalkanoyl group such as a phenylacetyl group or a phenoxyacetyl group; a lower alkoxycarbonyl group such as a methoxycarbonyl group, an ethoxycarbonyl group, a propyloxycarbonyl group, or a tert-butoxycarbonyl group; Benzyloxy Aralkyloxycarbonyl groups such as cicarbonyl group, p-nitrobenzeneoxycarbonyl group, phenethyloxy group carbonyl group; lower alkylsilyl groups such as trimethylsilyl group and tert-butyldimethylsilyl group; tetrahydrobiranyl group; trimethylsilyl Ethoxymethyl group; lower alkylsulfonyl group such as methylsulfonyl group and ethylsulfonyl group; arenylsulfonyl group such as benzene
- the hydroxyl-protecting group is not particularly limited as long as it has the function.
- a lower alkyl group such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a tert-butyl group; a trimethylsilyl group, Lower alkylsilyl groups such as tert-butyldimethylsilyl group; Lower alkoxymethyl groups such as methoxymethyl group and 2-methoxyethoxymethyl group; Tetrahydrobiranyl 'group; Trimethylolylyloxymethyl group; Benzyl group, p-methoxybe Aralkyl groups such as benzyl group, 2,3-dimethoxybenzyl group, o-nitrocarbenyl group, p-nitrile benzyl group, trityl group; and asinole groups such as formyl group and acetyl group;
- the protecting group for the carboxyl group is not particularly limited as long as it has the function, and examples thereof include lower alkyl groups such as a methyl group, an ethyl group, a propyl group, an isopropyl group, and a tert-butyl group; Halo lower alkyl groups such as 2,2-trichloroethyl group; lower alkenyl groups such as 2-propenyl group; benzyl group, p-methoxybenzyl group, p-nitrobenzyl group, benzhydryl group, Examples thereof include aralkyl groups such as a trityl group, and a methyl group, an ethyl group, a tert-butyl group, a 2_propenyl group, a benzyl group, a p-methoxybenzyl group, a benzhydryl group, and the like are particularly preferable.
- lower alkyl groups such as a methyl group, an e
- the protecting group for the oxo group and carbonyl group is not particularly limited as long as it has the function thereof, and examples thereof include acetals such as ethylene ketal, trimethylene ketal and dimethyl ketal, and ketals.
- the removal of the protecting group differs depending on the type of protecting group and the stability of the target compound [I].
- the method described in the literature [Protein G roupsin O rg anic Synthesis, TW Greene, John Wiley & Sons (1 981)] or a method analogous thereto, eg, solvolysis using acids or bases, eg, 0.01 mole to large excess Chemical reaction using a metal hydride complex or the like; Palladium, preferably trifluoroacetic acid, formic acid, hydrochloric acid, or the like; or an equimolar to large excess base, preferably hydroxylated power, calcium hydroxide, or the like; It can be carried out by catalytic reduction using a one-carbon catalyst, Raney nickel catalyst or the like.
- the protecting group P 2 of the compound represented by the formula [IV-b] is removed to obtain a compound represented by the formula [IV-c], and then the compound represented by the formula [IV-c].
- a compound represented by the formula [Va] are reacted according to the production method 1 to obtain a compound represented by the formula [I 1 1 P], and if the compound has a protecting group, the production method 3 Accordingly, the desired compound can be obtained by deprotection.
- ⁇ 3 2 and 0 3 are the same or different and represent a leaving group such as a halogen such as chlorine or bromine, a benzenesulfonyloxy group, a p-toluenesulfonyloxy group, a methanesulfonoxyl group, etc.
- L p, Z 2 p, W, R l P , R 2 p, X l P , X 2 p, X 3 , X 4 , X 5 , X 6 , X 7 and X 8 are the same as above is there.
- Bases include triethylamine, disopropylethylamine, pyridine,
- Amines such as 4-dimethylaminopyridine and tetrabutylanmolybdenum
- inorganic bases such as cesium carbonate, sodium carbonate, carbonated potassium, sodium hydride, hydrogenated power, lithium, sodium hydroxide, hydroxylated power
- organic bases such as sodium tert-butoxide and potassium tert-butoxide are exemplified.
- the amount of the base used is, for example, 1 mol to an excess mol per mol of the compound represented by the formula [Vb], preferably 2 mol to 10 mol is recommended.
- the amount of the compound represented by the formula [Vb] is exemplified by 1 mol to excess mol, preferably 5 mol to 20 mol, relative to 1 mol of the compound represented by the formula [I ⁇ _c]. Recommended.
- reaction solvent Shioi ⁇ methylene, chloride port Holm, Jikuroroetan, carbon tetrahalide such charcoal chloride arsenide; n - heptane, aliphatic hydrocarbons cyclohexane and the like n-; benzene, toluene, and xylene Aromatic hydrocarbons: Jetyl ether, TH Examples include ethers such as F, dioxane, and ethylene glycol dimethyl ether; solvents such as acetonitrile, NMP, DMF, and DMS O, and mixed solvents thereof.
- ethers such as F, dioxane, and ethylene glycol dimethyl ether
- solvents such as acetonitrile, NMP, DMF, and DMS O, and mixed solvents thereof.
- reaction temperature examples include 0 ° C. to 200 ° C., preferably 50 ° C. to 150 ° C., and the reaction is usually completed in 2 hours to 24 hours.
- a commercially available reagent can be used for the compound represented by the formula [V b].
- Examples of the base include inorganic bases such as cesium carbonate, sodium carbonate, and potassium carbonate.
- the base it can be 1 mol to excess mol, preferably 2 mol to 10 mol, per 1 mol of the compound represented by the formula [IV-d].
- Examples of the amount of the compound represented by the formula [V c] include 1 mol to excess mol, preferably 5 mol to 20 mol relative to 1 mol of the compound represented by the formula [IV-d]. Is recommended.
- reaction solvent salts Ihimechiren, black hole Holm, dichloro port:?” Tan, carbon tetrahalide such charcoal chloride arsenide; n - heptane, aliphatic hydrocarbons cyclohexane and the like n-; benzene, toluene, Examples include aromatic hydrocarbons such as xylene; ethers such as jetyl ether, THF, dioxane, ethylene glycol dimethyl ether; acetonitryl, NMP, DMF, DMSO, or a mixed solvent thereof.
- the reaction temperature is, for example, 0 ° C. to 200 ° C., preferably 20 ° C. to 150 ° C. is recommended, and the reaction is usually completed in 30 minutes to 12 hours.
- examples of the compound represented by the formula [V c] include dimethylamine, jetylamine, di-n-propylamine, N-ethylmethylamine, N-methyl'n-propylamine, N-methyl ⁇ "isopropinoleamine, N-ethynole n-propy ⁇ amine, N-ethylisopropylamine, aziridine, pyrrolidine ', piperidine, N-methylpiperazine, morpholine, methenoreamine, ethylamine, n-propylamine, isopropylamine, cyclopropylamine, n-Butylamine, sec-Butyla Min, tert-butylamine, cyclopropanemethylamine and the like are exemplified. Manufacturing method 5
- J represents a hydroxyl group or a leaving group such as a halogen such as chlorine or bromine, a benzenesulfonyloxy group, p.-toluenesulfonyloxy group, a methanesulfonyloxy group, or the like, and P Rb, Ar p , Y! p, y 2 p, W Xi P, X 2 p, X 3 , X 4 , X 5 , x 6 , 7 and 8 are the same as above],
- the protecting group Pi of the compound represented by the formula [IV—d] is removed to obtain a compound represented by the formula [I Ve], and then the compound represented by the formula [I V_e] and the formula [Vd And a compound represented by the formula [IV-f].
- the reaction of the compound represented by the formula [IV—e] with the compound in which J is a leaving group in the formula [Vd] is usually performed with respect to 1 mol of the compound represented by the formula [IV—e].
- Vd] can be carried out using 1 mol to excess mol, preferably 1 mol to 2 mol.
- bases include inorganic bases such as cesium carbonate, sodium carbonate, potassium carbonate, sodium hydride, hydrogen hydride, sodium hydroxide, and lithium hydroxide; Organic bases such as tert-butoxide and potassium tert-butoxide are exemplified, and cesium carbonate, sodium carbonate, potassium carbonate, sodium hydride and the like are recommended.
- reaction solvent examples include methylene chloride, black hole Holm, Jikuroroetan, halogenated carbons of the four coal chloride arsenide; n - heptane, aliphatic hydrocarbons cyclohexane and the like n-; benzene, toluene, aromatic or xylene
- hydrocarbons examples include ethers such as jetyl ether, THF, dioxane, ethylene glycol dimethyl ether; acetonitryl, NMP, DMF, DMSO, or a mixed solvent thereof.
- the reaction temperature is usually 20 ° C to 200 ° C, preferably 0 ° C to 100 ° C, and the reaction is usually completed in 2 hours to 24 hours.
- Rb, W have Q have X p, X 2 p, x 3, x 4, x 5, x 6, x 7 , and x 8 are as defined above. ]
- a compound represented by the formula [VI_a] is obtained by condensing a compound represented by the formula [II b] and a compound represented by the formula [III b] in a reaction solvent in the presence of a base. Get.
- Bases include amines such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, tetraptyl ammonium fluoride; cesium carbonate, sodium carbonate, lithium carbonate, hydrogenated sodium, hydrogenating power
- Inorganic bases such as lyme, sodium hydroxide and hydride power
- sodium tert examples thereof include organic bases such as butoxide and potassium tert-butoxide.
- the compound represented by the formula [IIIb] is exemplified by 1 mol to 2 mol, preferably 1 mol to 1.5 mol, per 1 mol. Is recommended.
- the amount of the base used is, for example, 1 mol to 3 mol, preferably 1 mol to 2 mol based on 1 mol of the compound represented by the formula [I I b].
- reaction solvent examples include methylene chloride, black hole Holm, Jikuroroetan, halogenated carbons of the four coal chloride arsenide; n - heptane, aliphatic hydrocarbons such as n-hexane; benzene, toluene ', aromatic or xylene carbide
- examples include hydrogens; ethers such as jetyl ether, THF, dioxane, ethylene glycol dimethyl ether; and acetonitryl, NMP DMF DMSO, and mixed solvents thereof.
- the reaction temperature is, for example, 20 ° C 200 ° C, preferably 0 ° C 100 ° C, and the reaction is usually completed in 5 minutes to 12 hours.
- Rb is (B)
- the compound represented by the formula [VI—a] can be reacted according to production method 4, and when Dp force S (b) Can be reacted according to production method 5, and production method 4 and production method 5 can be reacted in appropriate combination.
- Production method 8 provides a method for producing a compound represented by the formula [I 1 2 P] when Z is a carbon atom in formula [I].
- Reaction formula 9
- alcohol obtained by deprotecting the hydroxyl protecting group P 2 of the compound represented by the formula [VII-a] is mesylated (or tosylated, halogenated, etc.) by a conventionally known method.
- the compound represented by the formula [I 1 2P] can be obtained by reacting the obtained compound with an amine derivative represented by the formula [Vc] in the presence of a base.
- the method for removing the protective group P 2 for hydroxyl group and the method for mesylation (or introduction of a leaving group) may be carried out by a conventionally known method.
- the compound represented by the formula [VII—a] ([VII-a 1] or [VII—a 2] is a compound represented by the formula [II a] or the formula [lib] as shown in production method 9).
- the product can be obtained by condensing the product with a compound represented by the formula [Villa] or the formula [Villa]
- the reaction conditions may be determined according to the various production methods described above.
- ADDP is an abbreviation for ll ′ — (azodicarbonyl) dipiperidide
- R 3 is the same or different and represents a group selected from the group consisting of a hydrogen atom or group / 3
- R 4 is has the same meaning as R 3
- k 2 are the same as kl
- Q have X l
- X 5 X 6 X have X 8 and P 2 and K l are as defined above .
- a compound represented by the formula [I I a], a compound represented by the formula [I I b], or a derivative thereof can be prepared by the following production method.
- the compound can be prepared by the method described in the Examples, as far as a commercially available reagent can be used.
- Compound A can be a commercially available reagent or can be prepared by the method described in the Examples.
- the compound used in production method 10c can be prepared by the following method.
- Reaction formula 14 [Wherein Ar p is the same as defined above]
- the compound represented by the formula [III a], the compound represented by the formula [III b] or a derivative thereof, and the compounds represented by the formula [VIII] can be prepared by the following production method. . Manufacturing method 1 1
- R 5 represents a lower alkyl group
- X 5 represents a lower alkyl group
- RP k 1 and k 2 are the same as above
- the hydroxyl group of the compound represented by the formula [IX] is protected to form a compound represented by the formula [IX, and then the ester group of the compound represented by the formula [I Xa] is substituted with, for example, lithium aluminum hydride ( Reduction with LAH) yields the compound represented by the formula [Villa]. Then, the compound represented by the formula [VIII a] is obtained by introducing a leaving group such as tosylation, mesylation, halogenation, etc. into the compound represented by the formula [VIII a] by a known method. . ,
- R p, R 2 p, R 3, R 4, R 5, X 5, X 6, X 7, X 8, kl, k 2 ⁇ Are the same as above.
- the hydroxyl group of the compound represented by the formula [I X] is reacted according to the production method 8, and the compound represented by the formula (3 a ′) is obtained via the compound represented by the formula [I X b]. Then, the ester moiety of the compound represented by the formula (3 a ′) is reduced with, for example, LAH to obtain a compound represented by the formula [III a], and if necessary, represented by the formula [II lb]. It is also possible to make it a compound.
- the compound represented by the formula [I] obtained by the above method can be easily separated and purified by a conventionally known separation means.
- separation means include solvent extraction, recrystallization, column chromatography, liquid chromatography, preparative thin layer chromatography and the like.
- the compound of the present invention may have stereoisomers or tautomers such as optical isomers, diastereoisomers, and geometric isomers depending on the mode of the substituent. All steric differences 1 to living organisms, tautomers and mixtures thereof are also included. ,
- Membrane preparations prepared from cells expressing MCH-1R were combined with the test compound and 5 O pM [ 125 I] MCH (NEN), with Atsey buffer (10 mM magnesium chloride, 2 mM ethylenediamine 4 After incubation for 1 hour at 25 ° C in 5 OmM Tris buffer, pH 7.4) containing acetic acid, 0.0 1% bacitracin and 0.2% ushi serum albumin, glass filter GF / C (Whatman ). Glass filter with 10 mM magnesium chloride After washing with 50 mM Tris buffer, pH 7.4, containing 2 mM ethylenediaminetetraacetic acid and 0.04% Tween-20, the radioactivity on the glass filter was determined. Nonspecific binding was measured in the presence of ⁇ ⁇ human MCH, and the 50% inhibitory concentration (IC 50 value) of the test compound against specific [ 125 I] MCH binding was determined. The results are shown in Table 1.
- the compound of the present invention has MCH_1R antagonism, and obesity, diabetes, hormonal secretion abnormality, hyperlipidemia, gout, fatty liver, hepatitis, cirrhosis, etc., for example, angina Symptom, acute depressive heart failure, myocardial embolism, atherosclerosis, hypertension, kidney disease, electrolyte disorders, etc., eg bulimia, affective disorder, depression, anxiety, hemorrhoids, delirium, dementia, integration Central and peripheral nervous system diseases such as ataxia, attention deficit / hyperactivity disorder, memory disorder, sleep disorder, cognitive disorder, movement disorder, sensory abnormalities, olfactory disturbance, morphine tolerance, narcotic addiction, alcohol dependence,
- reproductive system diseases such as infertility, premature birth, sexual dysfunction, other gastrointestinal tract diseases, respiratory diseases, cancer or skin pigmentation, especially as a prophylactic or therapeutic agent for obesity It is.
- reproductive system diseases such as infertility, premature birth, sexual dysfunction, other gastrointestinal tract
- the compound of the present invention can be administered orally or parenterally, and by formulating it into a form suitable for its administration, obesity, diabetes, abnormal hormone secretion, hyperlipidemia, gout, fatty liver, Metabolic diseases such as hepatitis and cirrhosis, such as angina pectoris, acute congestive heart failure, myocardial infarction, atherosclerosis, hypertension, kidney disease, electrolyte abnormalities such as hyperphagia, affective disorder Depression, anxiety, epilepsy, delirium, dementia, schizophrenia, attention deficit / hyperactivity disorder, memory disorder, sleep disorder, cognitive disorder, movement disorder, sensory abnormality, olfactory disturbance, morphine tolerance, drug dependence, alcohol
- a preventive or therapeutic agent for central and peripheral nervous system diseases such as addiction, for example, reproductive system diseases such as infertility, premature birth, sexual dysfunction, etc., digestive tract diseases, respiratory diseases, cancer or skin pigmentation In particular it can serve as pre Bozai or therapeutic agent for obesity.
- the compound of the present invention When the compound of the present invention is used clinically, it is pharmaceutically acceptable in accordance with its administration form. It is also possible to add various carriers and administer after various preparations.
- various conventionally known additives in the pharmaceutical field can be used as the carrier, such as gelatin, lactose, sucrose, titanium oxide, starch, crystalline cellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, Corn starch, microcrystalline wax, white petrolatum magnesium metasilicate aluminate, anhydrous calcium phosphate, citrate, trisodium citrate, hydroxy lip oral cellulose, 'sorbitol, sonolebitan fatty acid ester, polysorbate, sucrose fatty acid ester, Polyoxetylene, hydrogenated castor oil, polybur'pyrrolidone, magnesium stearate, light anhydrous caustic acid, talc, vegetable oil, benzyl alcohol, arabia gum, propylene glycol And polyalkylene glycol ', cyclod
- dosage forms formulated as a mixture of these carriers and the compound of the present invention include solid preparations such as tablets, capsules, granules, powders or suppositories; or syrups, elixirs or injections, etc. These can be prepared according to conventionally known methods in the pharmaceutical field.
- a liquid preparation it may be in the form of “dissolving or suspending in water or other suitable medium at the time of use”.
- injections they may be dissolved or suspended in physiological saline or glucose solution as necessary, and buffers or preservatives may be added.
- the compound of the present invention is 1.0 to 100% by weight, preferably 1.0 to 60% by weight of the whole pharmaceutical composition. /.
- the pharmaceutically acceptable carrier can be contained in an amount of 0 to 99.0% by weight, preferably 40 to 99.0% by weight.
- These preparations may contain other therapeutically effective compounds such as a therapeutic agent for diabetes, a therapeutic agent for hypertension, a therapeutic agent for arteriosclerosis, and the like.
- the dose and the number of administrations are the patient's sex, age, weight, symptom level and the type of therapeutic effect although it can vary depending on the range, etc., the dosage is usually 0.0 1 to 5 O mg per day, and can be administered once or multiple times.
- the dosage is preferably from about 0.1 to about 25 mg / kg per day, more preferably from about 0.05 to about 1 O mg Z kg per day.
- the compound of the present invention contains hypertension, obesity-related hypertension, hypertension-related diseases, cardiac hypertrophy It can be used in combination with drugs that are effective for large, left ventricular hypertrophy, metabolic diseases, obesity, obesity-related diseases, etc. (hereinafter referred to as “combined drugs”). Such drugs can be administered simultaneously, separately or sequentially in the prevention or treatment of the disease.
- the compound of the present invention is used at the same time as one or more concomitant drugs, it can be made into a single-dose pharmaceutical thread preparation.
- the composition containing the compound of the present invention and the concomitant drug may be administered simultaneously, separately, or sequentially in a different package for the administration target. They may be administered at a time interval.
- the dose of the concomitant drug may be determined according to the dose used clinically, and can be appropriately selected depending on the administration target, administration route, disease, combination and the like.
- the administration form of the concomitant drug is not particularly limited as long as the compound of the present invention and the concomitant drug are combined at the time of administration. Examples of such administration forms include: 1) administration of a single preparation obtained by simultaneously formulating the compound of the present invention and a concomitant drug, 2) separate administration of the compound of the present invention and the concomitant drug Simultaneous administration of two preparations obtained by formulation in the same administration route, 3) Time difference in the same administration route of two preparations obtained by separately formulating the compound of the present invention and a concomitant drug.
- concomitant drug used in the present invention examples include “diabetes therapeutic drug”, “hyperlipidemic therapeutic drug”, “hypertension therapeutic drug”, “anti-obesity drug” and the like. Two or more of these concomitant drugs may be used in combination at an appropriate ratio.
- Glidazones glitazones
- glitazones eg ciglitazone, darglitazone, englitazone, isaglidazone
- Methoremin (metformin), buformin (buformin), phenformin ( biguanides such as phenformin;
- Meglitinides such as repagl inide, nateglinide
- amylase inhibitor such as tendamistat, trestatin, A 1 3688;
- Insulin secretion promoters such as linogliride and A-4166;
- Fatty acid oxidation inhibitors such as clomoxir, etomoxir 10) midaglizole, isaglidole, deriglidole, idazoxan, eraloxan, oxalan A2 antagonists such as;
- Non-thiazolidinediones such as J T—501 and farglitazar
- P P A R ⁇ ⁇ ⁇ biagonists such as MK-0767, CLX-0940, GW-1536, GW-1929, GW-2433, KRP_297, L-796449, LR-90 and SB219994.
- hypolipidemic agent examples include, for example,
- Cholesterol absorption inhibitors such as snatol 'ester, / 3—sitosterol, sterol glucoside, ezetimibe;
- Asylcoenzyme A cholesterol acyltransferase inhibitors such as avasimibe, eflucimibe, KY-505, SMP-709;
- CETP inhibitors such as JTT705, torcetrapib, CP532632, BAY-63-2149, SC-591, SC-795;
- FXR receptor antagonists such as GW-4064 and SR-103912
- L X R receptor agonists such as GW3965, T9013137, XTC0-179628;
- Lipoprotein synthesis inhibitors such as niacin
- Bile acid reabsorption inhibitors such as BARA1453, SC435, PHA384640, S-435, AZD7706;
- MTTP inhibitors such as LAB687 and CP346086;
- a platelet aggregation inhibitor 21) a platelet aggregation inhibitor; 22) 5-lipoxygenase activating protein inhibitors such as MK-591; Examples of the above-mentioned antihypertensive drug include
- Neutral endopeptidase inhibitors such as AVE7688 and ER4030;
- Endothelin antagonists such as tezosentan, A308165, YM62899;
- Vasodilators such as hydralazine, clonidine, minoxidil, nicotine alcohol;
- a 1 blockers such as terazosin, urapidil, prazosin, bunazosin, trimazosin,, doxazosin, naphthovir, indramine, WHIP164, XEN010;
- anti-obesity drugs examples include:
- 5HT (serotonin) transporter inhibitors such as paroxetine, fluoxetine, fenfluramine, fluvoxamine '(f luvoxamine), senotraline (sertraline), imipramine, etc .
- 5HT (serotonin) transporter inhibitors such as paroxetine, fluoxetine, fenfluramine, fluvoxamine '(f luvoxamine), senotraline (sertraline), imipramine, etc .
- GW320659 Norebinephrine transporter inhibitors such as desipramine, talsupram, nomifuncine;
- Ghrelin antagonists such as compounds disclosed in W001 / 87355, W002 / 08250, etc .;
- NPY 5 antagonists such as the compounds disclosed in (2000); 10) Leptins such as human recombinant leptin (PEG-OB, Hoffman La Roche), recombinant methylleptin (Amgen);
- nalmefene (Revex registered trademark), 3-methoxynal trexone, naloxone, nanoretrexone, an obioid antagonist such as a compound disclosed in W000 / 21509; 13) SB-334867A, other W001 / 96302, W001 / 68609, W002 / 51232, Aurexin antagonists such as compounds disclosed in W002 / 51838 and W003 / 023561;
- AR-R15849 GI-181771, JMV-180, A-71378, A_71623, SR-146131, Other Cholecystokinin A (CCK-A) agonists such as compounds disclosed in USP-5739106; 16) GI-181771 CNTF (cily iary neurotrophic factors) such as (Glaxo-SmithKline), SR146131 (Sanof i Synthelabo), Butabindide, PD170, 292, PD149164 (Fuaiza);
- CCK-A Cholecystokinin A
- axokine (Regeneron), other CNTF derivatives such as compounds disclosed in W094 / 09134, W098 / 22128, W099 / 43813;
- Sibutramine (Meridia registered trademark / Reductil registered trademark) and salts thereof, other USP4, 746, 680, USP4, 806, 570, USP5, 436, 272, US Patent Application No. 2002/0006964, W001 / 27068 and Monoamine reabsorption inhibitors such as derivatives disclosed in W001 / 62341;
- Fatty acid synthesis inhibitors such as callenin and C75;
- Oleoyl Estrone other acyl estrogens such as compounds disclosed in del Mar-Grasa, M. et al., Obesity Research, 9: 202-9 (2001);
- BVT3498, BVT2733, and other 11-/ 3 hydroxydehydrodehydrogenase type 1 inhibitors such as compounds disclosed in W001 / 90091, W001 / 90090, WOOl / 90092;
- Tetrahydroripatin (orlistat / Xenical registered trademark), TritonWR1339, RHC80267, Ribstatin, tea saponin, diethylumbelliferyl phosphate, FL-386, WAY-121898.
- Bay-N- 3176 Norilacton (valilactone), Estelacin (esteracin), Eberlactone A (ebelactone A), Everacton B (ebelactoneB), RHCS0267, etc.
- the above combination drug can be obtained by using one or more of the compound of the present invention and the above combination drug in combination.
- the above combination drug is useful for the prevention or treatment of metastatic disease by combining with one or more drugs selected from the group consisting of antidiabetic drugs and hyperlipidemia drugs. is there.
- hypertension treatment 'A combination containing a drug and an anti-obesity drug is useful for preventing or treating metastatic diseases with a synergistic effect by adding a drug for treating diabetes and / or a drug for treating hyperlipidemia.
- Initiator TM 60 (Biotage Japan Co., Ltd.) was used as the microwave organic synthesizer. Wakoge 1 TM C-200 or C-300 (Wako Pure Chemical Industries, Ltd.) is used as the silica gel for the power ram, and the FLASH + TM cartridge KP- Sil FLASH 1 2 + M is used as the packed silica gel column. , FLASH 25 + M, FLASH40 + M, etc. (Biotage 'Japan Co., Ltd.), and Y PLC—Pack TM pro C—18 etc.
- Reference Example 1 1 The same procedure as in Reference Example 1 was performed, except that 4-clonal benzyl alcohol used in (1) was replaced with (5-closal pyridin-2-yl) methanol. To give a compound.
- n-Butyllithium (2.6M n-hexane solution, 12.75 mL) was added to a THF solution (80 mL) of benzyl alcohol (5.21 mL, 50. Ommo 1) at 0 ° C. Stir for minutes.
- the reaction mixture was slowly added to a tetrahydrofuran suspension (8 Om L) of 2,4-dichloropyrimidine (5.00 g, 34. Ommo 1) and stirred at room temperature for 2.5 hours.
- saturated brine was added to the reaction mixture, and the mixture was extracted with ethyl acetate. After washing the organic layer with water and saturated saline, It was dried over magnesium sulfate and filtered.
- Reference Example 1 2- The same procedure as in Reference Example 1 2-2) except that the compound used in (2) was replaced with 2-methoxy 3- [4 (triphenylol) methyl] pyridine. The compound of Reference Example 13 was obtained.
- Reference Example 1 [4 (Trifluoromethyl) phenyl] polonic used in Reference Example 1 The same procedure as Reference Example 1 3 was performed, except that the cyd was replaced with the corresponding boronic acid compound. Reference Examples 14 and 1 5 compounds were obtained.
- Methyl [4- (bromomethyl) phenyl] acetate (0., 50 g, 2.1 Ommo 1) [J. Med. Ch em., 44 (5), 703 (2001)], pyrrolidine (0.35 mL, A mixture of 4.2 Ommo 1), potassium carbonate (1.45 g, 10.50 mm o 1) and NM P (10 mL) was stirred at room temperature for 2 days. Next, an aqueous sodium hydrogen carbonate solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with an aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and then filtered.
- the compound of Reference Example 17 was obtained in the same manner as in Reference Example 16, except that pyrrolidine used in Reference Example 16 was replaced with jetylamine.
- Reference Example 16 Metal, [4_ (pyrrolidine-1-ylmethyl) phenyl] acetate used in (2) was replaced with methylolene 4_ (pyrrolidine-1-monomethyl) ⁇ zolate [J. Med. Ch em., 38 Reference Example 16—The compound of Reference Example 18 was obtained in the same manner as in Reference Example 16— (2) except that the procedure was changed to (2), 234 (1 995)]. Mass spectrum (ES I): 1 92. 2 (M + H).
- Reference Example 1 6 Reference Example, except that the methyl [4- (pyrrolidine-1 monomethyl) phenol] acetate used in (2) was replaced with ethyl '(4 monobromo-1-fluorophenyl) acetate. The same operation as in 1 6 — (2) was performed to obtain the compound of Reference Example 19 (1) (3).
- Reference Example 1 Reference Example 1 except that the compound used in (2) is replaced with propyl 4- (2- ⁇ [tert-butyl (dimethyl) silyl] oxy ⁇ ethyl) — 3-Fluorobenzoate. 6—The same operation as in (2) was performed to obtain the compound of Reference Example 19 (6).
- Tetrabutylamine fluoride (1. OM THF solution, 2.2 mL) was added to the THF solution (l OmL) of the compound obtained in (7) above under ice-cooling, and the mixture was stirred at room temperature for 1 hour.
- a saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
- the obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- the obtained filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (black mouth form: methanolic acid 10: 0 to 9: 1) to obtain the title compound (274 mg, 66%).
- Reference Example 1 9 1 Methyl '2— (4 1 Promo 2-Fluorophenyl') Reference Example 19 1 (4) except that ethanol was replaced with methyl [4 (hydroxymethyl) phenyl] acetate ), And the compound of Reference Example 2 1— (1) was obtained.
- Reference Example 2 1—Methyl [4 (hydroxymethyl) phenyl '] acetate used in (1) was converted to methyl [6- (hydroxymethyl) pyridine 1 / - ⁇ ] acetate. 48-09 9 1 78) The compound of Reference Example 22 was obtained in the same manner as in Reference Example 21 except that
- tert-Butinore (4-Bromobenzenole) Methinolecarnocumate (2.0 g, 6.6 6 mm o 1) (WO 0 0 0 1 4 1 0 9) in DMF solution (2 OmL), tributyl (Biel ') Add stannane (2.3 4 mL 7. 99 mm o 1) and tetrakis (triphenylphosphine) palladium (38 5 mg, 0.3 3 mmo 1), and overnight at 80 ° C in the presence of nitrogen. Stir. Saturated brine was added to the reaction mixture, and the mixture was extracted with ether. 5 weight to the resulting organic layer.
- Reference Example 21 2- [4— ( ⁇ [tert-Butyl (dimethyl.) Silyl'oxy ⁇ methyl ') methanol] used in (3) was replaced with tert-butyl' [4- (.2— (Hydroxychetyl) benzyl]
- the compound of Reference Example 24 was obtained in the same manner as in Reference Example 21- (3) except that methylcarbamate was used.
- Reference Example 24 Reference was made except that tert-butyl (4-bromobenzyl) methylcarbamate used in (1) was replaced with 4-bromo-2-fluoro-1 — ⁇ [((4-methoxybenzinole) oxy] methyl ⁇ benzene. The same operation as in Example 24 was performed to obtain the compound of Reference Example 26.
- Reference Example 2 [4 — ( ⁇ [tert_Butyl (dimethyl) silyl] oxy ⁇ methyl) phenyl] ethanol used in 1— (3) 2— ⁇ 5 — [(Methoxymethyoxy) methyl '] Pyridine 2-ethanol ⁇ ethanol [J. Me d. C he m., 3 The same procedure as in Reference Example 2 1- (3) was carried out except that 9, 5 0 50, (1 9 9 6)] was obtained, and the compound of Reference Example 30 was obtained.
- Reference Example 2 2- (4- ( ⁇ [tert-Butyl (dimethyl) silinole] oxy ⁇ methinole) phenyl] Ethanol is used as an ethenore 4- (1, 1-difluoro mouthpiece 2-hydroxide
- the compound of Reference Example 31 was obtained in the same manner as Reference Example 21— (3) except that it was replaced with benzoate.
- Reference Example 16 Methyl [4- (pyrrolidine-1 1-ylmethyl) phenyl ⁇ acetate used in (2) was replaced with methyl '(4-bromophenyl) (fluoro) acetate The same operation as in Reference Example 16- (2) was carried out except that the compound was replaced with Sakai to obtain the compound of Reference Example 3 2- (2).
- Reference Example 20 [4- (1,3-Dioxane_2-ylmethyl) phenyl] used in Reference Example 20 was the same as Reference Example 20 except that ethanol was replaced with the corresponding known compound.
- Reference Example 33 And 34 compounds were obtained.
- Example 4 [(4 monofluorobenzyl ') oxy] pyridine 1 2 (1 H) —one and 2- [4- (pyrrolidine 1 1 ylmethyl) phenol] ethanol used in Example 1 were used as reference examples, respectively.
- the same operation as in Example 1 was performed except that the compound was replaced with a corresponding compound or a known compound to obtain the compound of Example 2_13.
- Example 14 1 The compound of Reference Example 3 and the compound of Reference Example 21 used in (1) were replaced with the corresponding compounds in Reference Example, and the same as that of Example 14-1 (4) was used.
- the compounds of Examples 15 to 41 were obtained in the same manner as in Example 14 except that the known amine compounds were used.
- Example 1 Example 1 Example from 4- (1) to Example 1 except that the compound of Reference Example 3 and the compound of Reference Example 21 used in (1) were changed to the corresponding compounds in Reference Example, respectively. 1 4- Perform the same procedure as in (3), and then use the obtained compound in place of the compound of Example 14 (1) used in Example 42 and further use isopropylamine. The same operation as in Example 42 was carried out except that the amine compound was used, and the compounds of Examples 4 3-5 3 were obtained.
- Example 54- (1) was obtained in the same manner as in Example 1, except that the compound of Reference Example 16 used in Example 1 was replaced with the compound of Reference Example 23- (2). Mass spectrum (E S I): 493.3 (M + H).
- TFA was added to the compound obtained in (1) above (341 mg, 0.69 mmo 1) and stirred at room temperature for 1 hour.
- the reaction mixture was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with ethyl acetate.
- the obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered.
- the obtained filtrate was concentrated under reduced pressure, diisopropyl ether was added to the residue, and the resulting solid was collected by filtration and dried to obtain the title compound (199 mg, 74%).
- Example 5 7 The compound of (1) was obtained.
- Example 14 1 The compound of Reference Example 21 used in (1) was replaced with the compound of Reference Example 23. Except for the above, the same operation as in Example 14-1 (1) was carried out, and tert-butyl 2- (4 1 ⁇ 2-[4 1 [(5--closed pyridine 1-yl) methoxy] 1 2 —Oxo 'pyridine 1 1 (2H) — ⁇ f-l] ethyl' ⁇ phenyl) pyrrolidine 1 1 1 carboxylate was obtained. Thereafter, the same procedure as in Example 54- (2) was carried out, except that the compound used in Example 54- (2) was changed to the above compound, to give the compound of Example 60. ⁇ NMR (40 OMH z, CD C 1 3. ⁇ ppm): 1.
- Example 55 [(5-Chromium 1-yl) methoxy '] — 1— ⁇ 2-[4— (1 1-Methylpyrrolidine 1-yl) phenyl] ethyl ⁇ 1-pyridine 2 (1 H)
- acetone used in Example 55 was replaced with a 35% aqueous formaldehyde solution
- the compound of Example 54 was replaced with the compound of Example 60.
- Example 70 was performed in the same manner as in Example 59, except that the compounds of Examples 70 and 71 were obtained.
- Example 70
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007529613A JPWO2007018248A1 (ja) | 2005-08-10 | 2006-08-03 | ピリドン化合物 |
CA002618112A CA2618112A1 (en) | 2005-08-10 | 2006-08-03 | Pyridone compound |
AU2006277253A AU2006277253A1 (en) | 2005-08-10 | 2006-08-03 | Pyridone compound |
EP06782591A EP1916239A4 (en) | 2005-08-10 | 2006-08-03 | PYRIDONE COMPOUND |
US11/989,876 US20100216758A1 (en) | 2005-08-10 | 2006-08-03 | Pyridone Compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-231995 | 2005-08-10 | ||
JP2005231995 | 2005-08-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007018248A1 true WO2007018248A1 (ja) | 2007-02-15 |
WO2007018248A9 WO2007018248A9 (ja) | 2008-02-14 |
Family
ID=37727430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/315775 WO2007018248A1 (ja) | 2005-08-10 | 2006-08-03 | ピリドン化合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100216758A1 (ja) |
EP (1) | EP1916239A4 (ja) |
JP (1) | JPWO2007018248A1 (ja) |
AU (1) | AU2006277253A1 (ja) |
CA (1) | CA2618112A1 (ja) |
WO (1) | WO2007018248A1 (ja) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
WO2008022979A1 (en) | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds |
WO2009103478A1 (en) * | 2008-02-19 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Pyridone and pyridazinone derivatives as mch antagonists |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8552199B2 (en) | 2009-02-13 | 2013-10-08 | Sanofi | Substituted indanes, method for the production thereof, and use thereof as drugs |
US8841290B2 (en) | 2009-02-13 | 2014-09-23 | Sanofi | Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs |
JP2015509517A (ja) * | 2012-03-07 | 2015-03-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mch−受容体モジュレーターとしてのピリジノン誘導体及びピリダジノン誘導体 |
WO2023242810A1 (en) | 2022-06-17 | 2023-12-21 | Richter Gedeon Nyrt. | Mchr1 antagonists for the treatment of prader-willi syndrome |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009261248A1 (en) * | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
JP5712481B2 (ja) | 2009-11-18 | 2015-05-07 | セントラル硝子株式会社 | 芳香族ジフルオロ酢酸エステルの製造方法 |
HU230880B1 (hu) | 2015-04-15 | 2018-11-29 | Richter Gedeon Nyrt | Indol származékok |
Citations (177)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4899178A (ja) | 1972-04-06 | 1973-12-15 | ||
US3914250A (en) | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
US4189438A (en) | 1977-02-08 | 1980-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Physiologically active substance esterastin |
US4405644A (en) | 1979-07-14 | 1983-09-20 | Bayer Aktiengesellschaft | Medicaments for the treatment of disorders of lipometabolism and their use |
US4452813A (en) | 1981-05-22 | 1984-06-05 | Taiho Pharmaceutical Company Limited | Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative |
US4476680A (en) | 1979-08-14 | 1984-10-16 | Sundstrand Corporation | Pressure override control |
US4598089A (en) | 1983-06-22 | 1986-07-01 | Hoffmann-La Roche Inc. | Leucine derivatives |
WO1989000528A1 (en) | 1987-07-22 | 1989-01-26 | Bertil Werjefelt | Operator station emergency visual assurance method and apparatus |
US4806570A (en) | 1981-04-06 | 1989-02-21 | The Boots Company Plc | Therapeutic agents |
US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
WO1993018035A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
WO1994009134A2 (en) | 1992-10-09 | 1994-04-28 | Regeneron Pharmaceuticals, Inc. | Modified ciliary neurotrophic factors |
US5391571A (en) | 1989-11-15 | 1995-02-21 | American Home Products Corporation | Cholesterol ester hydrolase inhibitors |
EP0658546A1 (fr) | 1993-12-17 | 1995-06-21 | Sanofi | Dérivés de 3-pyrazolecarboxamide avec une affinité pour le récepteur des cannabinoides |
US5436272A (en) | 1988-11-29 | 1995-07-25 | The Boots Company (Usa), Inc. | Treatment of obesity |
US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
WO1996014307A1 (en) | 1994-11-07 | 1996-05-17 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
WO1996023519A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023518A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023520A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023515A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023516A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023514A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023513A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
WO1996033159A1 (en) | 1995-04-21 | 1996-10-24 | Abbott Laboratories | Cyclobutane derivatives as inhibitors of squalene synthase and protein farnesyltransferase |
US5624941A (en) | 1992-06-23 | 1997-04-29 | Sanofi | Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present |
WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
WO1997029079A1 (fr) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Composes chimiques et utilisation pharmaceutique |
US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
US5739106A (en) | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
WO1998022128A1 (en) | 1996-11-19 | 1998-05-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity |
WO1998027063A1 (fr) | 1996-12-16 | 1998-06-25 | Banyu Pharmaceutical Co., Ltd. | Derives d'aminopyrazole |
WO1998031227A1 (en) | 1997-01-21 | 1998-07-23 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
WO1998033765A1 (en) | 1997-02-04 | 1998-08-06 | E.I. Du Pont De Nemours And Company | Fungicidal carboxamides |
WO1998037061A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Aktiengesellschaft | Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen |
WO1998041519A1 (en) | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
WO1998043956A1 (fr) | 1997-03-31 | 1998-10-08 | Eisai Co., Ltd. | Derives amines cycliques 1,4-substitues |
WO1998043636A1 (fr) | 1997-03-28 | 1998-10-08 | Sanofi-Synthelabo | Composition pharmaceutique pour administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs s olvates |
WO1998043635A1 (fr) | 1997-03-28 | 1998-10-08 | Sanofi-Synthelabo | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino- 3-pyrazolecarboxamide, de ses sels et de leurs solvates |
WO1999000123A1 (en) | 1997-06-26 | 1999-01-07 | Pharmacia & Upjohn Ab | Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity |
WO1999002499A1 (fr) | 1997-07-11 | 1999-01-21 | Japan Tobacco Inc. | Composes quinoline et utilisations de ceux-ci en medecine |
WO1999043813A1 (en) | 1998-02-27 | 1999-09-02 | Regeneron Pharmaceuticals, Inc. | Modified ciliary neurotrophic factor, method of making and methods of use thereof |
WO1999051600A1 (en) | 1998-04-02 | 1999-10-14 | Neurogen Corporation | AMINOALKYL SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES |
US6001836A (en) | 1997-05-28 | 1999-12-14 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: cyanoguanidine derivatives |
WO1999064002A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
US6028084A (en) | 1995-11-23 | 2000-02-22 | Sanofi-Synthelabo | Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives |
WO2000010968A2 (de) | 1998-08-19 | 2000-03-02 | Bayer Aktiengesellschaft | Neue aminosäureester von arylsulfonamiden und analoga |
WO2000010967A1 (de) | 1998-08-19 | 2000-03-02 | Bayer Aktiengesellschaft | Neue arylsulfonamide und analoga |
WO2000021509A2 (en) | 1998-10-15 | 2000-04-20 | Imperial College Innovations Limited | Methods of treatment |
EP1010691A2 (fr) | 1998-12-17 | 2000-06-21 | Adir Et Compagnie | Dérives de l'hydrazide, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
JP2000256190A (ja) | 1999-03-01 | 2000-09-19 | Pfizer Prod Inc | 甲状腺類似の抗肥満薬 |
EP1044970A1 (fr) | 1999-04-15 | 2000-10-18 | Adir Et Compagnie | Nouveaux composés aminotriazoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
US6140354A (en) | 1998-04-29 | 2000-10-31 | Ortho-Mcneil Pharmaceutical, Inc. | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
WO2000064880A1 (en) | 1999-04-22 | 2000-11-02 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
WO2000068197A1 (en) | 1999-05-05 | 2000-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS |
WO2000069849A1 (en) | 1999-05-12 | 2000-11-23 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
WO2000074679A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
WO2001002379A1 (en) | 1999-06-30 | 2001-01-11 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
WO2001007409A1 (en) | 1999-07-23 | 2001-02-01 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
WO2001009120A1 (en) | 1999-07-28 | 2001-02-08 | Ortho-Mcneil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
US6191160B1 (en) | 1998-11-10 | 2001-02-20 | Merck & Co., Inc. | Spiro-indolines as Y5 receptor antagonists |
WO2001014376A1 (en) | 1999-08-20 | 2001-03-01 | Banyu Pharmaceutical Co., Ltd. | Novel spiro compounds |
WO2001021577A2 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
WO2001023389A2 (en) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
WO2001023388A2 (en) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
WO2001023387A2 (en) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
WO2001027060A1 (de) | 1999-10-13 | 2001-04-19 | Haarmann & Reimer Gmbh | Verfahren zur herstellung von arylalkylethern |
WO2001027068A1 (en) | 1999-10-13 | 2001-04-19 | Pfizer Products Inc. | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
WO2001044201A1 (en) | 1999-12-16 | 2001-06-21 | Schering Corporation | Substituted imidazole neuropeptide y y5 receptor antagonists |
US6258837B1 (en) | 1997-04-23 | 2001-07-10 | Banyu Pharmaceutical Co., Ltd. | Neuropeptide Y receptor antagonist |
WO2001056592A1 (en) | 2000-02-01 | 2001-08-09 | Novo Nordisk A/S | Use of compounds for the regulation of food intake |
WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
JP2001226269A (ja) | 2000-02-18 | 2001-08-21 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
WO2001062737A2 (en) | 2000-02-24 | 2001-08-30 | Ortho-Mcneil Pharmaceutical, Inc. | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
WO2001062738A1 (fr) | 2000-02-22 | 2001-08-30 | Banyu Pharmaceutical Co., Ltd. | Composes a base d'imidazoline |
WO2001062341A2 (en) | 2000-02-22 | 2001-08-30 | Knoll Gmbh | Combination product for the treatment of obesity |
WO2001064633A1 (fr) | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation |
WO2001064632A1 (fr) | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
WO2001064634A1 (fr) | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
WO2001066548A1 (en) | 2000-03-06 | 2001-09-13 | F. Hoffmann-La Roche Ag | New aza-indolyl derivatives |
WO2001068609A1 (en) | 2000-03-14 | 2001-09-20 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivatives |
WO2001070708A1 (en) | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
WO2001070337A1 (en) | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
WO2001074844A2 (en) | 2000-04-04 | 2001-10-11 | F. Hoffmann-La Roche Ag | Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity |
WO2001074782A1 (en) | 2001-03-29 | 2001-10-11 | Molecular Design International, Inc. | β3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME |
WO2001077094A1 (en) | 2000-04-07 | 2001-10-18 | Aventis Pharma Deutschland Gmbh | Percyquinnin, a process for its production and its use as a pharmaceutical |
WO2001082925A1 (fr) | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Antagonistes de l'hormone concentrant la melanine |
WO2001085730A1 (en) | 2000-05-09 | 2001-11-15 | Astrazeneca Ab | Pyrido' 1,2-alpha pyrazine and piperidine derivatives as ligands for the neuropeptide y y5 receptor |
WO2001085098A2 (en) | 2000-05-10 | 2001-11-15 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine npy antagonists |
WO2001085173A1 (en) | 2000-05-10 | 2001-11-15 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine npy antagonists |
WO2001085714A1 (en) | 2000-05-05 | 2001-11-15 | Astrazeneca Ab | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor |
WO2001085690A1 (en) | 2000-05-10 | 2001-11-15 | Bristol-Myers Squibb Company | 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine npy antagonists |
WO2001087834A1 (fr) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Antagoniste de l'hormone de concentration de la melanine |
WO2001087355A1 (en) | 2000-05-18 | 2001-11-22 | Australian Rural Group Limited | Lipophilic medicament |
WO2001090090A1 (en) | 2000-05-22 | 2001-11-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
WO2001091752A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Melanocortin receptor agonists |
US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
WO2001096302A1 (en) | 2000-06-16 | 2001-12-20 | Smithkline Beecham P.L.C. | Piperidines for use as orexin receptor antagonists |
WO2001096330A2 (en) | 2000-06-15 | 2001-12-20 | Schering Corporation | Thrombin receptor antagonists |
US6337332B1 (en) | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
WO2002002744A2 (en) | 2000-07-05 | 2002-01-10 | Synaptic Pharmaceutical Corporation | Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
US20020006964A1 (en) | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
WO2002004433A2 (en) | 2000-07-06 | 2002-01-17 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
WO2002006245A1 (en) | 2000-07-05 | 2002-01-24 | Synaptic Pharmarceutical Corporation | Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
WO2002008250A2 (en) | 2000-07-24 | 2002-01-31 | Ardana Bioscience Limited | Ghrelin antagonists |
WO2002010169A1 (en) | 2000-07-31 | 2002-02-07 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
WO2002012178A1 (en) | 2000-08-07 | 2002-02-14 | Melacure Therapeutics Ab | Compounds acting as melanocortin receptor ligands |
WO2002011715A2 (en) | 2000-08-07 | 2002-02-14 | Melacure Therapeutics Ab | The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
WO2002012166A2 (en) | 2000-08-04 | 2002-02-14 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
US20020022637A1 (en) | 2000-05-11 | 2002-02-21 | Li James J. | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
WO2002015909A1 (en) | 2000-08-23 | 2002-02-28 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
WO2002015905A1 (en) | 2000-08-21 | 2002-02-28 | Gliatech, Inc. | The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity |
WO2002015845A2 (en) | 2000-08-21 | 2002-02-28 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
WO2002020488A2 (en) | 2000-09-06 | 2002-03-14 | F. Hoffmann-La Roche Ag | Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
WO2002022592A2 (en) | 2000-09-14 | 2002-03-21 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
US6365633B1 (en) | 1999-03-19 | 2002-04-02 | Knoll Pharmaceutical Company | Method of treating eating disorders |
WO2002032898A2 (de) | 2000-10-14 | 2002-04-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue anticholinergika, verfahren zu deren herstellung und deren verwendung als arzneimittel |
WO2002032888A1 (en) | 2000-10-13 | 2002-04-25 | Eli Lilly And Company | Substituted dipeptides as growth hormone secretagogues |
US20020049196A1 (en) | 1995-12-28 | 2002-04-25 | Carpino Philip A. | Growth-hormone secretagogues |
WO2002036596A2 (en) | 2000-11-03 | 2002-05-10 | Wyeth | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES |
WO2002040457A1 (en) | 2000-11-20 | 2002-05-23 | Biovitrum Ab | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
WO2002040456A1 (en) | 2000-11-20 | 2002-05-23 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
WO2002044152A1 (en) | 2000-10-16 | 2002-06-06 | F. Hoffmann-La Roche Ag | Indoline derivatives and their use as 5-ht2 receptor ligands |
WO2002048124A2 (en) | 2000-12-15 | 2002-06-20 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
WO2002048152A2 (en) | 2000-12-12 | 2002-06-20 | Neurogen Corporation | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines |
WO2002049648A1 (en) | 2000-12-21 | 2002-06-27 | Schering Corporation | Heteroaryl urea neuropeptide y y5 receptor antagonists |
WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
WO2002051809A1 (en) | 2000-12-22 | 2002-07-04 | Schering Corporation | Piperidine mch antagonists and their use in the treatment of obesity |
WO2002051844A1 (en) | 2000-12-27 | 2002-07-04 | F. Hoffmann-La Roche Ag | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
WO2002059108A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Melanocortin receptor agonists |
WO2002059107A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
WO2002059095A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Melanocortin receptor agonists |
WO2002062764A1 (en) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
WO2002068387A2 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
WO2002067869A2 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
WO2002068388A2 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
WO2002076929A1 (en) | 2001-03-21 | 2002-10-03 | Pharmacopeia, Inc. | Aryl and biaryl compounds having mch modulatory activity |
WO2002076949A1 (en) | 2001-03-22 | 2002-10-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2002076947A1 (en) | 2001-03-21 | 2002-10-03 | Schering Corporation | Mch antagonists and their use in the treatment of obesity |
WO2002081454A1 (en) | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
WO2002083128A1 (en) | 2001-04-12 | 2002-10-24 | Bristol-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method |
WO2002083134A1 (en) | 2001-04-12 | 2002-10-24 | Pharmacopeia, Inc. | Aryl and biaryl piperidines used as mch antagonists |
EP1258476A1 (fr) | 2001-05-15 | 2002-11-20 | Les Laboratoires Servier | Dérivés d'alpha-amino-acides, leur procédé de préparation ainsi que leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV (DPP IV) |
WO2002094789A1 (en) | 2001-05-21 | 2002-11-28 | F. Hoffmann-La Roche Ag | Quinoline derivatives as ligands for the neuropeptide y receptor |
WO2002094799A2 (en) | 2001-05-22 | 2002-11-28 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
WO2003000181A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2003000250A1 (en) | 2001-06-25 | 2003-01-03 | Ferring Bv | 3-fluoro-pyrrolidines as antidiabetic agents |
WO2003000180A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2003002553A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
WO2003002539A1 (fr) | 2001-06-27 | 2003-01-09 | Ube Industries, Ltd. | Compose de dibenzocycloheptene |
WO2003002530A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
WO2003002531A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
WO2003004496A1 (en) | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
WO2003004498A1 (en) | 2001-07-06 | 2003-01-16 | Merck & Co., Inc. | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2003004027A1 (en) | 2001-07-05 | 2003-01-16 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as mch selective antagonists |
WO2003006007A1 (en) | 2001-07-11 | 2003-01-23 | Research & Innovation Soc.Coop. A R.L. | Use of compounds as functional antagonists to the central cannabinoid receptors |
WO2003007949A1 (en) | 2001-07-18 | 2003-01-30 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
WO2003009847A1 (en) | 2001-07-25 | 2003-02-06 | Amgem, Inc. | Substituted piperidines as modulators of the melanocortin receptor |
WO2003023561A2 (en) | 2001-09-12 | 2003-03-20 | Rockwell Automation Technologies, Inc. | Network independent safety protocol for industrial controller using data manipulation techniques |
WO2003068230A1 (en) | 2002-02-14 | 2003-08-21 | Pharmacia Corporation | Substituted pyridinones as modulators of p38 map kinase |
WO2004069798A1 (ja) * | 2003-02-10 | 2004-08-19 | Banyu Pharmaceutical Co.,Ltd. | ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤 |
WO2005049589A2 (en) * | 2003-10-14 | 2005-06-02 | Cadila Healthcare Limited | Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases |
WO2006009789A2 (en) * | 2004-06-17 | 2006-01-26 | Neurogen Corporation | Aryl-substituted piperazine derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4552854B2 (ja) * | 2003-05-21 | 2010-09-29 | 萬有製薬株式会社 | 2−アミノキノリン誘導体 |
CA2558272C (en) * | 2004-03-05 | 2011-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone derivative |
WO2005108399A1 (ja) * | 2004-05-10 | 2005-11-17 | Banyu Pharmaceutical Co., Ltd. | イミダゾピリジン化合物 |
AU2005290436A1 (en) * | 2004-10-01 | 2006-04-13 | Banyu Pharmaceutical Co.,Ltd | 2-arylcarboxamide-nitrogeneous heterocycle compound |
-
2006
- 2006-08-03 JP JP2007529613A patent/JPWO2007018248A1/ja not_active Withdrawn
- 2006-08-03 WO PCT/JP2006/315775 patent/WO2007018248A1/ja active Application Filing
- 2006-08-03 US US11/989,876 patent/US20100216758A1/en not_active Abandoned
- 2006-08-03 CA CA002618112A patent/CA2618112A1/en not_active Abandoned
- 2006-08-03 EP EP06782591A patent/EP1916239A4/en not_active Withdrawn
- 2006-08-03 AU AU2006277253A patent/AU2006277253A1/en not_active Abandoned
Patent Citations (190)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4899178A (ja) | 1972-04-06 | 1973-12-15 | ||
US3914250A (en) | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
US4189438A (en) | 1977-02-08 | 1980-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Physiologically active substance esterastin |
US4242453A (en) | 1977-02-08 | 1980-12-30 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Cultivating streptomyces to produce an esterase inhibitor |
US4405644A (en) | 1979-07-14 | 1983-09-20 | Bayer Aktiengesellschaft | Medicaments for the treatment of disorders of lipometabolism and their use |
US4476680A (en) | 1979-08-14 | 1984-10-16 | Sundstrand Corporation | Pressure override control |
US4806570A (en) | 1981-04-06 | 1989-02-21 | The Boots Company Plc | Therapeutic agents |
US4452813A (en) | 1981-05-22 | 1984-06-05 | Taiho Pharmaceutical Company Limited | Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative |
US4598089A (en) | 1983-06-22 | 1986-07-01 | Hoffmann-La Roche Inc. | Leucine derivatives |
WO1989000528A1 (en) | 1987-07-22 | 1989-01-26 | Bertil Werjefelt | Operator station emergency visual assurance method and apparatus |
US5436272A (en) | 1988-11-29 | 1995-07-25 | The Boots Company (Usa), Inc. | Treatment of obesity |
US5391571A (en) | 1989-11-15 | 1995-02-21 | American Home Products Corporation | Cholesterol ester hydrolase inhibitors |
US5512565A (en) | 1989-11-15 | 1996-04-30 | American Home Products Corporation | Cholesterol ester hydrolase inhibitors |
US5602151A (en) | 1989-11-15 | 1997-02-11 | American Home Products Corporation | Cholesterol ester hydrolase inhibitors |
US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
WO1993018035A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
US5624941A (en) | 1992-06-23 | 1997-04-29 | Sanofi | Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present |
WO1994009134A2 (en) | 1992-10-09 | 1994-04-28 | Regeneron Pharmaceuticals, Inc. | Modified ciliary neurotrophic factors |
US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
EP0658546A1 (fr) | 1993-12-17 | 1995-06-21 | Sanofi | Dérivés de 3-pyrazolecarboxamide avec une affinité pour le récepteur des cannabinoides |
US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
WO1996014307A1 (en) | 1994-11-07 | 1996-05-17 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
WO1996023518A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023519A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023515A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023516A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023514A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023513A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023517A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023520A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
WO1996033159A1 (en) | 1995-04-21 | 1996-10-24 | Abbott Laboratories | Cyclobutane derivatives as inhibitors of squalene synthase and protein farnesyltransferase |
US20020006964A1 (en) | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
US5739106A (en) | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
US6028084A (en) | 1995-11-23 | 2000-02-22 | Sanofi-Synthelabo | Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives |
WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
US20020049196A1 (en) | 1995-12-28 | 2002-04-25 | Carpino Philip A. | Growth-hormone secretagogues |
WO1997029079A1 (fr) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Composes chimiques et utilisation pharmaceutique |
WO1998022128A1 (en) | 1996-11-19 | 1998-05-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity |
WO1998027063A1 (fr) | 1996-12-16 | 1998-06-25 | Banyu Pharmaceutical Co., Ltd. | Derives d'aminopyrazole |
WO1998031227A1 (en) | 1997-01-21 | 1998-07-23 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
WO1998033765A1 (en) | 1997-02-04 | 1998-08-06 | E.I. Du Pont De Nemours And Company | Fungicidal carboxamides |
WO1998037061A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Aktiengesellschaft | Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen |
WO1998041519A1 (en) | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
WO1998043635A1 (fr) | 1997-03-28 | 1998-10-08 | Sanofi-Synthelabo | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino- 3-pyrazolecarboxamide, de ses sels et de leurs solvates |
WO1998043636A1 (fr) | 1997-03-28 | 1998-10-08 | Sanofi-Synthelabo | Composition pharmaceutique pour administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs s olvates |
WO1998043956A1 (fr) | 1997-03-31 | 1998-10-08 | Eisai Co., Ltd. | Derives amines cycliques 1,4-substitues |
US6258837B1 (en) | 1997-04-23 | 2001-07-10 | Banyu Pharmaceutical Co., Ltd. | Neuropeptide Y receptor antagonist |
US6001836A (en) | 1997-05-28 | 1999-12-14 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: cyanoguanidine derivatives |
WO1999000123A1 (en) | 1997-06-26 | 1999-01-07 | Pharmacia & Upjohn Ab | Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity |
WO1999002499A1 (fr) | 1997-07-11 | 1999-01-21 | Japan Tobacco Inc. | Composes quinoline et utilisations de ceux-ci en medecine |
WO1999043813A1 (en) | 1998-02-27 | 1999-09-02 | Regeneron Pharmaceuticals, Inc. | Modified ciliary neurotrophic factor, method of making and methods of use thereof |
WO1999051600A1 (en) | 1998-04-02 | 1999-10-14 | Neurogen Corporation | AMINOALKYL SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES |
US6140354A (en) | 1998-04-29 | 2000-10-31 | Ortho-Mcneil Pharmaceutical, Inc. | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
WO1999064002A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
WO2000010968A2 (de) | 1998-08-19 | 2000-03-02 | Bayer Aktiengesellschaft | Neue aminosäureester von arylsulfonamiden und analoga |
WO2000010967A1 (de) | 1998-08-19 | 2000-03-02 | Bayer Aktiengesellschaft | Neue arylsulfonamide und analoga |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
US6337332B1 (en) | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
WO2000021509A2 (en) | 1998-10-15 | 2000-04-20 | Imperial College Innovations Limited | Methods of treatment |
US6313298B1 (en) | 1998-11-10 | 2001-11-06 | Merck & Co., Inc. | Spiro-indolines as Y5 receptor antagonists |
US6191160B1 (en) | 1998-11-10 | 2001-02-20 | Merck & Co., Inc. | Spiro-indolines as Y5 receptor antagonists |
EP1010691A2 (fr) | 1998-12-17 | 2000-06-21 | Adir Et Compagnie | Dérives de l'hydrazide, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
JP2000256190A (ja) | 1999-03-01 | 2000-09-19 | Pfizer Prod Inc | 甲状腺類似の抗肥満薬 |
US6365633B1 (en) | 1999-03-19 | 2002-04-02 | Knoll Pharmaceutical Company | Method of treating eating disorders |
EP1044970A1 (fr) | 1999-04-15 | 2000-10-18 | Adir Et Compagnie | Nouveaux composés aminotriazoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
WO2000064880A1 (en) | 1999-04-22 | 2000-11-02 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
WO2000068197A1 (en) | 1999-05-05 | 2000-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS |
WO2000069849A1 (en) | 1999-05-12 | 2000-11-23 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
WO2000074679A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
WO2001002379A1 (en) | 1999-06-30 | 2001-01-11 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
WO2001007409A1 (en) | 1999-07-23 | 2001-02-01 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
WO2001009120A1 (en) | 1999-07-28 | 2001-02-08 | Ortho-Mcneil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
WO2001014376A1 (en) | 1999-08-20 | 2001-03-01 | Banyu Pharmaceutical Co., Ltd. | Novel spiro compounds |
US6326375B1 (en) | 1999-08-20 | 2001-12-04 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
US6335345B1 (en) | 1999-08-20 | 2002-01-01 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
WO2001021577A2 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
WO2001023389A2 (en) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
WO2001023388A2 (en) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
WO2001023387A2 (en) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
WO2001027060A1 (de) | 1999-10-13 | 2001-04-19 | Haarmann & Reimer Gmbh | Verfahren zur herstellung von arylalkylethern |
WO2001027068A1 (en) | 1999-10-13 | 2001-04-19 | Pfizer Products Inc. | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
WO2001044201A1 (en) | 1999-12-16 | 2001-06-21 | Schering Corporation | Substituted imidazole neuropeptide y y5 receptor antagonists |
WO2001056592A1 (en) | 2000-02-01 | 2001-08-09 | Novo Nordisk A/S | Use of compounds for the regulation of food intake |
WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
JP2001226269A (ja) | 2000-02-18 | 2001-08-21 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
WO2001062341A2 (en) | 2000-02-22 | 2001-08-30 | Knoll Gmbh | Combination product for the treatment of obesity |
WO2001062738A1 (fr) | 2000-02-22 | 2001-08-30 | Banyu Pharmaceutical Co., Ltd. | Composes a base d'imidazoline |
WO2001062737A2 (en) | 2000-02-24 | 2001-08-30 | Ortho-Mcneil Pharmaceutical, Inc. | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
WO2001064632A1 (fr) | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
WO2001064634A1 (fr) | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
WO2001064633A1 (fr) | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation |
WO2001066548A1 (en) | 2000-03-06 | 2001-09-13 | F. Hoffmann-La Roche Ag | New aza-indolyl derivatives |
WO2001068609A1 (en) | 2000-03-14 | 2001-09-20 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivatives |
WO2001070708A1 (en) | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
WO2001070337A1 (en) | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
WO2001074844A2 (en) | 2000-04-04 | 2001-10-11 | F. Hoffmann-La Roche Ag | Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity |
WO2001077094A1 (en) | 2000-04-07 | 2001-10-18 | Aventis Pharma Deutschland Gmbh | Percyquinnin, a process for its production and its use as a pharmaceutical |
WO2001082925A1 (fr) | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Antagonistes de l'hormone concentrant la melanine |
WO2001085714A1 (en) | 2000-05-05 | 2001-11-15 | Astrazeneca Ab | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor |
WO2001085730A1 (en) | 2000-05-09 | 2001-11-15 | Astrazeneca Ab | Pyrido' 1,2-alpha pyrazine and piperidine derivatives as ligands for the neuropeptide y y5 receptor |
WO2001085690A1 (en) | 2000-05-10 | 2001-11-15 | Bristol-Myers Squibb Company | 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine npy antagonists |
WO2001085173A1 (en) | 2000-05-10 | 2001-11-15 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine npy antagonists |
WO2001085098A2 (en) | 2000-05-10 | 2001-11-15 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine npy antagonists |
US20020022637A1 (en) | 2000-05-11 | 2002-02-21 | Li James J. | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
WO2001087834A1 (fr) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Antagoniste de l'hormone de concentration de la melanine |
WO2001087355A1 (en) | 2000-05-18 | 2001-11-22 | Australian Rural Group Limited | Lipophilic medicament |
WO2001090091A1 (en) | 2000-05-22 | 2001-11-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
WO2001090092A1 (en) | 2000-05-22 | 2001-11-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
WO2001090090A1 (en) | 2000-05-22 | 2001-11-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
WO2001091752A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Melanocortin receptor agonists |
WO2001096330A2 (en) | 2000-06-15 | 2001-12-20 | Schering Corporation | Thrombin receptor antagonists |
WO2001096302A1 (en) | 2000-06-16 | 2001-12-20 | Smithkline Beecham P.L.C. | Piperidines for use as orexin receptor antagonists |
WO2002002744A2 (en) | 2000-07-05 | 2002-01-10 | Synaptic Pharmaceutical Corporation | Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
WO2002006245A1 (en) | 2000-07-05 | 2002-01-24 | Synaptic Pharmarceutical Corporation | Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
WO2002004433A2 (en) | 2000-07-06 | 2002-01-17 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
WO2002008250A2 (en) | 2000-07-24 | 2002-01-31 | Ardana Bioscience Limited | Ghrelin antagonists |
WO2002010169A1 (en) | 2000-07-31 | 2002-02-07 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
WO2002012166A2 (en) | 2000-08-04 | 2002-02-14 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
WO2002012178A1 (en) | 2000-08-07 | 2002-02-14 | Melacure Therapeutics Ab | Compounds acting as melanocortin receptor ligands |
WO2002011715A2 (en) | 2000-08-07 | 2002-02-14 | Melacure Therapeutics Ab | The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
WO2002015905A1 (en) | 2000-08-21 | 2002-02-28 | Gliatech, Inc. | The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity |
WO2002015845A2 (en) | 2000-08-21 | 2002-02-28 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
WO2002015909A1 (en) | 2000-08-23 | 2002-02-28 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
WO2002020488A2 (en) | 2000-09-06 | 2002-03-14 | F. Hoffmann-La Roche Ag | Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
WO2002022592A2 (en) | 2000-09-14 | 2002-03-21 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
WO2002032888A1 (en) | 2000-10-13 | 2002-04-25 | Eli Lilly And Company | Substituted dipeptides as growth hormone secretagogues |
WO2002032898A2 (de) | 2000-10-14 | 2002-04-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue anticholinergika, verfahren zu deren herstellung und deren verwendung als arzneimittel |
WO2002044152A1 (en) | 2000-10-16 | 2002-06-06 | F. Hoffmann-La Roche Ag | Indoline derivatives and their use as 5-ht2 receptor ligands |
WO2002036596A2 (en) | 2000-11-03 | 2002-05-10 | Wyeth | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES |
WO2002040456A1 (en) | 2000-11-20 | 2002-05-23 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
WO2002040457A1 (en) | 2000-11-20 | 2002-05-23 | Biovitrum Ab | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
WO2002048152A2 (en) | 2000-12-12 | 2002-06-20 | Neurogen Corporation | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines |
WO2002048124A2 (en) | 2000-12-15 | 2002-06-20 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
WO2002049648A1 (en) | 2000-12-21 | 2002-06-27 | Schering Corporation | Heteroaryl urea neuropeptide y y5 receptor antagonists |
WO2002051809A1 (en) | 2000-12-22 | 2002-07-04 | Schering Corporation | Piperidine mch antagonists and their use in the treatment of obesity |
WO2002051844A1 (en) | 2000-12-27 | 2002-07-04 | F. Hoffmann-La Roche Ag | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
WO2002051838A1 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists |
WO2002059117A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
WO2002059108A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Melanocortin receptor agonists |
WO2002059107A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
WO2002059095A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Melanocortin receptor agonists |
WO2002062764A1 (en) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
WO2002068387A2 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
WO2002067869A2 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
WO2002068388A2 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
WO2002076929A1 (en) | 2001-03-21 | 2002-10-03 | Pharmacopeia, Inc. | Aryl and biaryl compounds having mch modulatory activity |
WO2002076947A1 (en) | 2001-03-21 | 2002-10-03 | Schering Corporation | Mch antagonists and their use in the treatment of obesity |
WO2002076949A1 (en) | 2001-03-22 | 2002-10-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2001074782A1 (en) | 2001-03-29 | 2001-10-11 | Molecular Design International, Inc. | β3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME |
WO2002081454A1 (en) | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
WO2002083134A1 (en) | 2001-04-12 | 2002-10-24 | Pharmacopeia, Inc. | Aryl and biaryl piperidines used as mch antagonists |
WO2002083128A1 (en) | 2001-04-12 | 2002-10-24 | Bristol-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method |
EP1258476A1 (fr) | 2001-05-15 | 2002-11-20 | Les Laboratoires Servier | Dérivés d'alpha-amino-acides, leur procédé de préparation ainsi que leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV (DPP IV) |
WO2002094789A1 (en) | 2001-05-21 | 2002-11-28 | F. Hoffmann-La Roche Ag | Quinoline derivatives as ligands for the neuropeptide y receptor |
WO2002094799A2 (en) | 2001-05-22 | 2002-11-28 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
WO2003000181A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2003000180A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2003000250A1 (en) | 2001-06-25 | 2003-01-03 | Ferring Bv | 3-fluoro-pyrrolidines as antidiabetic agents |
WO2003002531A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
WO2003002539A1 (fr) | 2001-06-27 | 2003-01-09 | Ube Industries, Ltd. | Compose de dibenzocycloheptene |
WO2003002530A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
WO2003002553A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
WO2003004496A1 (en) | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
WO2003004027A1 (en) | 2001-07-05 | 2003-01-16 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as mch selective antagonists |
WO2003004498A1 (en) | 2001-07-06 | 2003-01-16 | Merck & Co., Inc. | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2003006007A1 (en) | 2001-07-11 | 2003-01-23 | Research & Innovation Soc.Coop. A R.L. | Use of compounds as functional antagonists to the central cannabinoid receptors |
WO2003007949A1 (en) | 2001-07-18 | 2003-01-30 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
WO2003009847A1 (en) | 2001-07-25 | 2003-02-06 | Amgem, Inc. | Substituted piperidines as modulators of the melanocortin receptor |
WO2003023561A2 (en) | 2001-09-12 | 2003-03-20 | Rockwell Automation Technologies, Inc. | Network independent safety protocol for industrial controller using data manipulation techniques |
WO2003068230A1 (en) | 2002-02-14 | 2003-08-21 | Pharmacia Corporation | Substituted pyridinones as modulators of p38 map kinase |
WO2004069798A1 (ja) * | 2003-02-10 | 2004-08-19 | Banyu Pharmaceutical Co.,Ltd. | ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤 |
WO2005049589A2 (en) * | 2003-10-14 | 2005-06-02 | Cadila Healthcare Limited | Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases |
WO2006009789A2 (en) * | 2004-06-17 | 2006-01-26 | Neurogen Corporation | Aryl-substituted piperazine derivatives |
Non-Patent Citations (56)
Title |
---|
"body color change", INTERNATIONAL REVIEW OF CYTOLOGY, vol. 126, no. 1, 1991 |
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 261, 1999, pages 622 |
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 268, no. 88, 2000 |
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 283, 2001, pages 1013 |
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 289, 2001, pages 44 |
BIOCHIMICA ET BIOPHISICA ACTA, vol. 1401, 1998, pages 216 |
CANADIAN JOURNAL OF CHEMISTRY, vol. 68, no. 2, 1990, pages 314 - 16 |
CRITICAL REVIEWS IN NEUROBIOLOGY, vol. 8, 1994, pages 221 |
DEL MAR-GRASA, M. ET AL., OBESITY RESEARCH, vol. 9, 2001, pages 202 - 9 |
DIABETES, DIABETES, vol. 47, no. 294, 1998 |
DYCK B. ET AL.: "A Thienopyridazinone-Based Melanin-Concentrating Hormone Receptor 1 Antagonist with Potent in Vivo Anorectic Properties", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 13, 29 June 2006 (2006-06-29), pages 3753 - 3756, XP003003117 * |
ENDOCRINOLOGY, vol. 137, 1996, pages 561 |
FEBS LETTERS, vol. 398, 1996, pages 253 |
FEBS LETTERS, vol. 457, 1999, pages 522 |
GENOMICS, vol. 79, 2002, pages 785 |
J. MED. CHEM., vol. 38, no. 2, 1995, pages 234 |
J. MED. CHEM., vol. 39, 1996, pages 5050 |
J. MED. CHEM., vol. 44, no. 5, 2001, pages 703 |
J.O.C., vol. 57, no. 7, 1988, pages 1367 - 1371 |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 3, 1989, pages 709 - 15 |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 11, 2003, pages 2216 - 2226 |
JOURNAL OF NEUROENDOCRINOLOGY, vol. 8, 1996, pages 57 |
KAWAUCHI ET AL.: "from sermon hypophysis.", NATURE, vol. 305, no. 321, 1983 |
LAZEWSKA, D. ET AL., PHARMAZIE, vol. 56, 2001, pages 927 - 32 |
MOLECULAR BRAIN RESEARCH, vol. 92, no. 43, 2001 |
MOLECULAR MEDICINE TODAY, vol. 6, 2000, pages 43 |
MOLECULAR PHARMACOLOGY, vol. 60, 2001, pages 632 |
NATURE CELL BIOLOGY, vol. 1, 1999, pages 267 |
NATURE, vol. 380, no. 243, 1996 |
NATURE, vol. 396, no. 670, 1998 |
NATURE, vol. 400, 1999, pages 261 |
NATURE, vol. 400, no. 265, 1999 |
NEUROENDOCRINOLOGY, vol. 61, 1995, pages 348 |
NORMAN ET AL., J. MED. CHEM., vol. 43, 2000, pages 4288 - 4312 |
PEPTIDES, vol. 15, 1994, pages 757 |
PEPTIDES, vol. 17, no. 171, 1996 |
PEPTIDES, vol. 18, no. 1095, 1997 |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, 2001, pages 7564 |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, 2001, pages 7576 |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, 2002, pages 3240 |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 3240, 2002 |
REIDEMEISTER, S. ET AL., PHARMAZIE, vol. 55, 2000, pages 83 - 6 |
SASSE, A. ET AL., ARCH. PHARM, vol. 334, 2001, pages 45 - 52 |
SASSE, A. ET AL., J. MED. CHEM., vol. 43, 2000, pages 3335 - 43 |
See also references of EP1916239A4 * |
T. W. GREENE: "Protective Groups in Organic Synthesis", 1981, JOHN WILEY & SONS |
TETRAHEDRON, vol. 49, no. 7, 1993, pages 1445 |
TETRAHEDRON, vol. 60, no. 31, 2004, pages 6461 - 6474 |
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, 2001, pages 20125 |
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, 2001, pages 34664 |
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 107, 2001, pages 379 |
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 109, 2002, pages 923 |
THE JOURNAL OF COMPARATIVE NEUROLOGY, vol. 319, no. 218, 1992 |
THE JOURNAL OF COMPARATIVE NEUROLOGY, vol. 435, 2001, pages 26 |
TRENDS, ENDOCRINOLOGY AND METABOLISM, vol. 5, no. 120, 1994 |
TRENDS, NEUROSCIENCE, vol. 24, 2001, pages 527 |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
US8067590B2 (en) | 2006-08-25 | 2011-11-29 | Boehringer Ingelheim International Gmbh | Pyridone derivates with MCH antagonistic activity and medicaments comprising these compounds |
EP2383259A1 (en) | 2006-08-25 | 2011-11-02 | Boehringer Ingelheim International GmbH | New pyridone derivatives with MCH antagonistic activity and medicaments comprising these compounds |
AU2007287601B2 (en) * | 2006-08-25 | 2012-12-20 | Boehringer Ingelheim International Gmbh | New pyridone derivatives with MCH antagonistic activity and medicaments comprising these compounds |
JP2010501518A (ja) * | 2006-08-25 | 2010-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mch拮抗作用を有する新規ピリドン誘導体及びこの化合物を含む薬物 |
WO2008022979A1 (en) | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds |
WO2009103478A1 (en) * | 2008-02-19 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Pyridone and pyridazinone derivatives as mch antagonists |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US8552199B2 (en) | 2009-02-13 | 2013-10-08 | Sanofi | Substituted indanes, method for the production thereof, and use thereof as drugs |
US8841290B2 (en) | 2009-02-13 | 2014-09-23 | Sanofi | Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
JP2015509517A (ja) * | 2012-03-07 | 2015-03-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mch−受容体モジュレーターとしてのピリジノン誘導体及びピリダジノン誘導体 |
WO2023242810A1 (en) | 2022-06-17 | 2023-12-21 | Richter Gedeon Nyrt. | Mchr1 antagonists for the treatment of prader-willi syndrome |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007018248A1 (ja) | 2009-02-19 |
EP1916239A1 (en) | 2008-04-30 |
CA2618112A1 (en) | 2007-02-15 |
US20100216758A1 (en) | 2010-08-26 |
AU2006277253A1 (en) | 2007-02-15 |
WO2007018248A9 (ja) | 2008-02-14 |
EP1916239A4 (en) | 2009-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007018248A1 (ja) | ピリドン化合物 | |
AU2005219784B2 (en) | Pyridone derivative | |
WO2007024004A1 (ja) | フェニルピリドン誘導体 | |
WO2007029847A1 (ja) | 二環性芳香族置換ピリドン誘導体 | |
KR101318127B1 (ko) | 아자 치환된 스피로 유도체 | |
WO2006038680A1 (ja) | 2-アリールカルボキサミド-含窒素複素環化合物 | |
AU2004209505B2 (en) | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | |
WO2005108399A1 (ja) | イミダゾピリジン化合物 | |
WO2009154132A1 (ja) | スピロジアミン-ジアリールケトオキシム誘導体 | |
WO2008038692A1 (fr) | dÉrivÉ de diarylcÉtimine | |
US20100324049A1 (en) | Diaryl ketimine derivative having antagonism against melanin-concentrating hormone receptor | |
AU2004241213B2 (en) | 2-aminoquinoline derivative | |
CA2717384A1 (en) | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism | |
AU2004265189A1 (en) | Imidazopyridine derivatives | |
WO2010147234A1 (en) | Diarylamide-spirodiamine derivative | |
WO2010050456A1 (ja) | ジ又はトリアリールメチル構造を有するピペリジン化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007529613 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11989876 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2618112 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006277253 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006782591 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006277253 Country of ref document: AU Date of ref document: 20060803 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1419/DELNP/2009 Country of ref document: IN |